抑制性受体ILTs及其配体在胃癌表达的实验和临床研究
|
摘要
研究背景:
胃癌是严重危害人类健康的恶性疾病,全球每年有超过93万新发的胃癌病例,胃癌死亡率约为29.34/10万(男性40.80/10万,女性18.60/10万),是世界范围高居第二位的癌症死亡原因。据卫生部疾控司2006年统计,我国每年新发胃癌患者约40万人,因胃癌死亡患者约30万人,患病率和死亡率超过世界平均水平的两倍。近年来,国内外学者对胃癌的发生及转移进行了大量的基础和临床研究,取得了部分成果。但在胃癌的发病机制、早期诊断、干预治疗和预后判断方面,仍处于积极的探索阶段。因此深入研究胃癌的发病机制,探讨胃癌发病过程中肿瘤和免疫细胞的功能及状态,对研究胃癌及干预治疗无疑具有重要的指导意义。
胃癌的病因目前仍不十分清晰。流行病学研究发现,胃癌的发病与饮食因素、感染因素、遗传因素及其他环境因素有关。近年最新的研究认为,胃癌的发生发展是宿主免疫系统和胃癌细胞相互作用的结果,不仅涉及到宿主效应细胞多种功能(T淋巴细胞数量和功能异常、活化障碍及凋亡增加)及细胞因子(IFN-γ含量降低、IL-10含量升高等)的改变,还与胃癌细胞自身的异常(缺乏协同刺激分子、MHC表达降低或缺失、FasL高表达)及相关癌基因及抑癌基因异常密切相关。其中肿瘤细胞表面缺少共刺激分子的表达是免疫逃逸的主要原因。目前发现共刺激分子有两种,即正性共刺激分子和负性共刺激分子。正性共刺激分子通过与淋巴细胞的受体结合共刺激免疫反应,影响T细胞的活化、增殖及细胞因子分泌。而负性共刺激分子通过两种方法来诱导T细胞无能：一是诱导抑制因子表达在效应性免疫细胞上,二是诱导抑制性因子受体表达在肿瘤细胞上。
免疫球蛋白样转录子(Ig-like transcripts,ILTs)或白细胞抑制受体是最近发现的一类HLA-I受体家族,目前发现有九个家族成员,在T淋巴细胞、单个核细胞、NK细胞及树突状细胞表面广泛表达。不同种类的ILTs通过传导抑制性或刺激性信号发挥广泛的免疫调节作用,在抑制免疫杀伤细胞的杀伤活性、调节树突状细胞与T细胞间的信号传递、参与树突状细胞的抗原俘获等方面具有重要的生物学意义。其中ILT2、ILT3、ILT4属抑制性受体,其结构共同特点是有一个长的膜内段,含有3个免疫受体酪氨酸抑制基序,有4个或2个膜外的IgSF区。该类因子的功能主要是抑制分子,但其在肿瘤细胞上的表达和功能尚不清楚。
HLA-G分子是一种非经典HLA-I类抗原,该基因具有8个外显子和7个内含子。HLA-G分子在结构上胞内段很短,并且原始的HLA-G转录产物经选择性剪切产生7种mRNA,编码出7种HLA-G蛋白异构体。其中HLA-G1和HLA-G5可以高特异性结合ILT2、ILT4,且与ILT2、LT4结合亲和力比经典HLA-I与ILT2, ILT4亲和大3-4倍。HLA-G分子通过抑制免疫活性细胞的功能在免疫耐受的建立和维持中发挥关键作用。HLA-G可通过与NK细胞、T细胞、APC等细胞表面的抑制性受体ILT-2、ILT-4等结合发挥抑制性免疫调节作用。可溶性HLA-G(sHLA-G)还可与CD8+细胞受体结合,诱导NK细胞和T细胞的凋亡、抑制同种特异性T细胞的细胞周期进程。除此之外,研究显示,HLA-G还可诱导调节性T细胞和抑制性NK细胞的产生,并可在很大程度上通过移植细胞颗粒极化来保护靶细胞不被NK细胞和T细胞杀伤。HLA-G分子除表达于胎盘绒毛膜细胞、肿瘤细胞外,还可少量表达在众多组织细胞上,包括T淋巴细胞。而胃癌患者中淋巴细胞HLA-G表达变化如何?作为抑制性受体ILT2、ILT4等的主要配体,在不同分化程度胃癌发生过程中所起作用如何,目前尚不清晰。
研究目的和方法：
一、本研究采用实时荧光定量PCR-Sybr Green I和FACS流式细胞术等方法对人的高分化胃癌细胞株(MKN1)、中分化胃癌细胞株(SGC-7901、AGS)、低分化胃癌细胞株(MGC803)和未分化分化胃癌细胞株(HGC-27、BCG823)中的mRNA和蛋白表达进行了检测和分析,系统地探讨了ILT2、ILT3和ILT4在不同分化程度的人胃癌细胞中的表达变化,为后期试验和相关研究提供了试验依据。
二、为了探讨不同表达程度的抑制性受体ILTs对免疫细胞的影响,我们通过体外细胞试验,将ILT2lowILT3lowILT4low胃癌细胞MKNI和ILT2highILT3highILT4high胃癌细胞HGC-27分别与PBMC和NK细胞共培养,通过检测细胞杀伤活性(MTT),CD4+、CD8+T淋巴细胞和NK细胞上HLA-G分子的表达改变探讨抑制性受体ILTs对效应细胞的调控作用。
三、为进一步探讨抑制性受体ILT2、ILT3和ILT4在临床应用中的价值,采用免疫组织化学方法检测了临床不同分化程度胃癌患者病理组织中ILT2、ILT3和ILT4的表达,并探讨了其与肿瘤生物学行为和临床特征的关系。
四、为了探讨作为抑制性受体ILTs主要配体的HLA-G在临床胃癌患者淋巴细胞中的表达变化,应用TaqMan探针FQ-PCR和FACS流式细胞术对不同分化胃癌患者外周血淋巴细胞HLA-G mRNA和CD4+、CD8+T淋巴细胞上HLA-G分子表达及其与临床进程的关系进行了初步分析。
以上研究通过体外细胞试验和临床应用研究,系统的探讨了抑制性受体ILT2、ILT3和ILT4在不同分化程度的胃癌细胞中的表达变化及其对效应细胞的影响,期望为阐明胃癌发生和转移的分子机制提供实验依据,同时为临床胃癌的诊断、防治和新药开发寻找新的靶目标提供依据。
结果及结论：
一、胃癌细胞株抑制性受体ILTs mRNA和蛋白表达
1.实时荧光定量PCR-Sybr Green I检测结果表明,6株不同分化程度的人胃癌细胞均不同程度表达了ILT2、ILT3和ILT4 mRNA,尤以ILT2表达最强。其中在高分化的胃癌细胞株MKN1中ILT2、ILT3和ILT4 mRNA表达最低,未分化胃癌细胞株HGC-27和BCG823的mRNA表达最高,显示随分化程度存在显著性差异。
2.FACS流式细胞术检测显示,6株胃癌细胞中除一株未分化胃癌细胞BCG823表达ILT3、ILT4极低外,其余均检测到ILT2、ILT3和ILT4不同程度的蛋白表达,且其表达程度与肿瘤细胞分化相关,尤以ILT2表现最明显。
上述实验结果表明,通过某种共同信号途径使恶性程度高的胃癌细胞高表达抑制性受体ILT2、ILT3和ILT4,并可能影响到效应细胞的功能及对肿瘤的杀伤。
二、抑制性受体ILTs对效应细胞调控的实验研究
1.ILT2highILT3highILT4high胃癌细胞HGC-27与PBMC、NK细胞共培养后效应细胞杀伤活性(MTT)较ILT2lowILT3lowILT4low胃癌细胞MKN1与PBMC、NK细胞共培养后效应细胞杀伤活性显著降低,初步表明胃癌细胞不同表达程度的ILT2、ILT3、ILT4影响PBMC、NK细胞的增殖和杀伤作用。
2.ILT2highILT3highILT4high的HGC-27细胞和ILT2lowILT3lowILT4low的MKNl细胞分别与PBMC和NK细胞共培养24h后,与各自对照相比,T细胞和NK细胞表面HLA-G的表达明显变化,且ILT2highILT3highILT4high的HGC-27细胞对HLA-G的影响较ILT2lowILT3lowILT4low的MKN1细胞更明显。其中T淋巴细胞HLA-G主要表达于CD4+T细胞,CD8+T细胞表达很低或基本不表达；CD56+NK细胞表达结果显示同样的趋势,但总体表达水平较CD4+细胞低。
实验结果提示胃癌细胞上ILT2、ILT3和ILT4分子表达对效应细胞的杀伤活性有影响,并可能对HLA-G的表达有一定的调控作用。
三、胃癌患者ILT表达的临床应用研究
免疫组织化学分析显示,50例不同组织类型、不同分化程度的胃癌患者病理组织中ILT2、ILT3和ILT4分子有不同程度的表达。在肿瘤细胞上的表达形式是散在的,可位于胃癌细胞膜或胞浆内或两者皆有,病灶周围的基质细胞也有部分表达。ILT2、ILT3和ILT4表达阳性率在50例胃癌组织标本中差异较大。其中ILT2表达阳性率最高,为62.0%(31/50),ILT3、ILT4表达阳性率分别为18.0%(9/50)和34%(17/50),正常胃组织中未见ITL2,ILT3, ILT 4的表达。提示抑制性受体ILTs,尤其是ILT2有可能成为胃癌临床诊断的有价值指标,并为胃癌临床干预治疗提供新的靶点。
四、胃癌患者淋巴细胞非经典HLA-G的表达
1.通过TaqMan探针FQ-PCR检测发现,胃癌患者及健康对照淋巴细胞HLA-G mRNA,总体表达水平较弱。其中,胃癌临床分级Ⅰ+Ⅱ期的患者与健康对照相比相对表达量无显著性差异(P>0.05)；临床分级Ⅲ+Ⅳ期患者转录水平较Ⅰ+Ⅱ期相对表达量低(P<0.05)。而从临床病理组织分化程度分析,分化良好型与低分化型胃癌患者HLA-G mRNA表达未见明显改变。
2.通过FACS流式细胞仪检测发现,无论健康对照和胃癌患者,淋巴细胞HLA-G分子表达阳性率均较低。与同型对照相比,CD8+T细胞基本不表达,HLA-G分子表达主要集中于CD4+T淋巴细胞,且表达阳性率在不同胃癌患者中变化幅度较大,可能与肿瘤微环境及相关影响有关。
Background:
Gastric Cancer is one of the most frequent malignant tumors which are harmful to human health.There are more than 9.3 million newly discovered cases annually in the world. The death rate of Gastric Cancer is approximately 29.34 per million (man 40.80 per million and woman 18.60 per million respectively) that is second larger in the world. According to Ministry of Health statistics in 2006, the number of Gastric Cancer patients is as many as 4 million, and 3 million people die of this disease every year in our country. Recently many scholars study the cause and diversion of Gastric Cancer and acquire some success. However, we are still in double regarding the mechanism of cancer, early diagnosis and estimate of prognostic. Thus, it is significant to research the mechanism of cancer and to discuss the state and function of immunocyte during the process of tumor. There is no doubt that it will be beneficial to understand and cure Gastric Cancer.
At present, the pathogen of this cancer is not clear. Epidemiology research suggests the cause of Gastric Cancer relates to many factors such as food, infection and inheritance. Recently, it is considered that the process of Gastric Cancer is an interaction between immune system and cancer cells in host. It involves not only change of effector cell functions (abnormal quantity and function of T lymphocyte) and some cytokines (IFN-y and IL-10), but also the abnormal tumor cell self (high expression of FasL and lack of co-stimulatory molecules and decrease of MHC) and relevant oncogene and anti-oncogene modification. Among all the factors above, the lack of co-stimulatory molecules which are expressed on the cancer cell surface is one of the most important reasons that results in immune evasion. Positive stimulatory molecules influence activation and proliferation of T lymphocyte while negative ones inhibit the function of T lymphocyte through the follow two ways:they induce inhibitory factors to express on effect cells and tumor cells.
Ig-like transcript (ILT) which is also called leukocyte inhibitory receptor(LIR) is a kind of newly discovered receptor family which recognize HLA-I. At present,9 members of the ILT family are known and they are expresses on a wide range of cells which include T lymphocyte, monocyte, NK and dendrite cells. Different kinds of ILTs play a great role in immunologic modification by transmitting inhibitory or simulative signals, for instance, in term of inhibiting activity of killer cells and regulating signal transmission between dendrite cells and T lymphocytes and so on. Inhibitory receptors (ILT2, ILT3, ILT4) consist 4 or 2 extracellular C-2 type Ig-SF domains and possess long cytoplasm tails that contain 3 immunoreceptor tyrosine-based inhibitory motifs (ITIMs). However, the expression and function of these receptors have not been well understood on tumors.
HLA-G molecule is one kind of nonclassical antigen and possesses a shore cytoplasm domain. HLA-G gene contains 8 extrons and 7 introns. Alternative splicing of the primary transcripts results in seven different mRNA, encoding four membrane-anchored (HLA-G1,G2,G3,G4) and three soluble (HLA-G5,G6,G7) isoforms, in which HLA-G 1 and HLA-G5 can combine ILT2 and ILT4 with high specificity. HLA-G plays an important part in establishing and maintaining immune tolerance by inhibiting the function of immune cells. HLA-G molecule exerts suppressive role via integrating with ILT2 and ILT4 which be expressed in NK cells, T lymphocytes and APC. Soluble HLA-G(sHLA-G) molecule also can link cells receptor with CD8+thus induces apoptosis of NK and T lymphocytes. Besides, the latest research suggests that HLA-G molecule can tempt the produce of Tregs and inhibitory NK cells, and protect the target cells from being damaged by NK and T lymphocytes to a large extent. HLA-G molecule can be primarily expressed on the surface of trophoblast cells and cancer cells. There are also a few HLA-G molecules which can be expressed on the surface of histiocytes, such as T lymphocyte. However, we are still wondering in the variety of HLA-G on T lymphocytes of patients with Gastric Cancer, which is main ligand for inhibitory receptor ILT2 and ILT4.
Objectives and Methods:
Ⅰ. We analyzed the mRNA and protein expression of well-differentiated Gastric Cancer cell lines (MKN1), moderate differentiation Gastric Cancer cell lines (SGC-7901、AGS), poorly differentiated cell lines(MGC803) and undifferentiation cell lines (HGC-27、BCG823) respectively by fluorescent quantization PCR-Sybr GreenⅠand FACS flow cytometer. And we discussed the variety of ILT2, ILT3, ILT4 in diverse differentiation of Gastric Cancer cell lines systemically, which provide experimental evidence for succedent research.
Ⅱ. In order to explore the effect of the different degree expression of inhibiting ILTs to immune cells, we try to investigate that different leveles of inhibitory ILTs influence immunocytes in vitro. We cultureed well-differentiated Gastric Cancer cell lines (MKN1), which express slight ILT2/ILT3/ILT4, and undifferentiation Gastric Cancer cell lines (HGC-27), which express substantial ILT2/ILT3/ILT4, with PBMC and NK together respectively, and tested MTT and HLA-G in CD4+、CD8+T lymphocytes and NK to discuss the role that inhibitory ILT regulate effector cells.
Ⅲ. Immunohistochemistry was used to detect the expression of ILT2/ILT3/ILT4 in pathologic tissue with diverse differentiation from patients who surfer Gastric Cancer to make further efforts to explore the value of ILT2/ILT3/ILT4 in clinical application.
Ⅳ. We also introduced TaqMan probe FQ-PCR and FACS flow cytometer to inspect the expression of HLA-G that is ligand for ILTs in PBMC and CD4+、CD8+T lymphocyte, and to research the changes of HLA-G and analyse the relation between Gastric Cancer phase and the expression of HLA-G molecule preliminarily.
In a word, from this part of research we discussed systemically the variety of ILT2, 3,4 in diverse differentiation of Gastric Cancer cell lines and their effect on immunocytes. It is expected to provide experimental evidence to illustrate the mechanism for the growth and metastasis of tumor and theoretical basis simultaneously for the diagnosis and treatment of Gastric Cancer and the exploiture of new drugs.
Results and Conclusions:
I. Expression of inhibitory ILTs mRNA and protein of human gastric cancer:an experiment study in vitro
1. Using fluorescent quantization PCR-Sybr Green I, we detected the expression of ILT2,3,4 mRNA from 6 Gastric Cancer cell lines with diverse differentiation. From the results, we can see that all the differentiation groups express various extents ILT mRNA, and ILT2 mRNA is expressed the highest especially. In the mean time, well-differentiated Gastric Cancer cell lines (MKN1) express the lowest amount of ILTs among them and, on the contrary, undifferentiation Gastric Cancer cell lines (HGC-27 and BCG823) express the highest amount of ILTs. There is significant difference in 6 cell lines with diverse differentiation.
2. We found that ILT2,3,4 are expressed with different extent in nearly all differentiation groups except undifferentiation Gastric Cancer cell lines (BCG823), which express little ILT3 and ILT4, and the different levels of ILTs relates to the differentiation of tumor cells by FACS flow cytometer.
Experimental results above demonstrate that malignant Gastric Cancer cells can express ILT2/ILT3/ILT4 through some common pathway, which influence the function of effector cells and their killer activity to tumor cells.
II Inhibitory ILTs regulation to effector cells:an experiment study in vitro
l.By coculture ILT2highILT3highILT4high HGC-27 cell and ILT2lowILT3lowILT4low MKN1 cell with PBMC、NK respectively, we found that the killer activity of effector cells was reduced distinctly, and the former was more prominence than latter. Thus, we considered that varying degree of ILT2/ILT3/ILT4 that were expressed by human stomach cancer cell influences the proliferation and killer activity of PBMC and NK cells.
2. Coculture were obtained as described above for 24 hours, we conclued that HLA-G at the surface of T. and NK cells varies markedly and ILT2highILT3highILT4hig HGC-27 had a more significant effect on HLA-G than those by ILT2lowILT3lowILT4low MKN1. Inaddition, HLA-G that is expressed at the surface of T lymphocytes mainly located CD4+T lymphocytes, and there was little even no HLA-G at the surface of CD8+T lymphocytes. Besides, HLA-G expressed on CD56+NK cells is lower than that in T lymphocytes.
Experimental results indicated that ILT2/ILT3/ILT4 have an impact on the killer activity of effector cells, and may regulate the expression of HLA-G..
III. Expression of inhibitory ILTs on gastric cancers:a clinical study
The expression of ILT2/ILT3/ILT4 from 50 Gastric Cancer pathological tissues were tested. From the results, we can see that it is dissimilar with diverse differentiation and type of tumor, and ILT2/ILT3/ILT4 cound be expressed either in cytoplasm or membrane of Gastric Cancer cells and even both. The positive rate of ILT2,ILT3 and ILT4 expression among 50 Gastric Cancer pathological tissues also varies a lot, and the positive rate of ILT2 is the highest-62.0%(31/50), while the positive rate of ILT3 and ILT4 is 18.0%(9/50) and 34%(17/50) respectively. There was no ILT2/ILT3/ILT4 on normal tissues, which indicated that inhibitory ILTs, especially ILT2, may be a valuable index for diagnosing Gastric Cancer and provide a new target to treat gastric cancer.
IV. Expression of non-classical HLA-G on PBLs of gastric cancers:a clinical study
1. By Fluorescent quantitation RT-PCR, we considered that HLA-G mRNA in both lymphocytes from Gastric Cancer and healthy control was weak, and there was no significant difference betweenⅠ+ⅡGastric Cancer and healthy control (P>0.05) However, HLA-G mRNA inⅢ+ⅣGastric Cancer was lower than that inⅠ+Ⅱ(P< 0.05). Also, there is no distinct change between well-differentiated and poorly differentiated Gastric Cancer in term of clinical differentiation.
2. By FACS Flow Cytometry, we found that the expression of HLA-G on lymphocytes both from Gastric Cancer and healthy control was low, and there was nearly no HLA-G expression on CD8+T lymphocytes of patients of Gastric Cancer. On the contrary, HLA-G molecules were mainly expressed on CD4+T lymphocytes, and the positive rate was also different in diverse patients, which was associated with tumor microenvironment and other influence factor.
胃癌是严重危害人类健康的恶性疾病,全球每年有超过93万新发的胃癌病例,胃癌死亡率约为29.34/10万(男性40.80/10万,女性18.60/10万),是世界范围高居第二位的癌症死亡原因。据卫生部疾控司2006年统计,我国每年新发胃癌患者约40万人,因胃癌死亡患者约30万人,患病率和死亡率超过世界平均水平的两倍。近年来,国内外学者对胃癌的发生及转移进行了大量的基础和临床研究,取得了部分成果。但在胃癌的发病机制、早期诊断、干预治疗和预后判断方面,仍处于积极的探索阶段。因此深入研究胃癌的发病机制,探讨胃癌发病过程中肿瘤和免疫细胞的功能及状态,对研究胃癌及干预治疗无疑具有重要的指导意义。
胃癌的病因目前仍不十分清晰。流行病学研究发现,胃癌的发病与饮食因素、感染因素、遗传因素及其他环境因素有关。近年最新的研究认为,胃癌的发生发展是宿主免疫系统和胃癌细胞相互作用的结果,不仅涉及到宿主效应细胞多种功能(T淋巴细胞数量和功能异常、活化障碍及凋亡增加)及细胞因子(IFN-γ含量降低、IL-10含量升高等)的改变,还与胃癌细胞自身的异常(缺乏协同刺激分子、MHC表达降低或缺失、FasL高表达)及相关癌基因及抑癌基因异常密切相关。其中肿瘤细胞表面缺少共刺激分子的表达是免疫逃逸的主要原因。目前发现共刺激分子有两种,即正性共刺激分子和负性共刺激分子。正性共刺激分子通过与淋巴细胞的受体结合共刺激免疫反应,影响T细胞的活化、增殖及细胞因子分泌。而负性共刺激分子通过两种方法来诱导T细胞无能：一是诱导抑制因子表达在效应性免疫细胞上,二是诱导抑制性因子受体表达在肿瘤细胞上。
免疫球蛋白样转录子(Ig-like transcripts,ILTs)或白细胞抑制受体是最近发现的一类HLA-I受体家族,目前发现有九个家族成员,在T淋巴细胞、单个核细胞、NK细胞及树突状细胞表面广泛表达。不同种类的ILTs通过传导抑制性或刺激性信号发挥广泛的免疫调节作用,在抑制免疫杀伤细胞的杀伤活性、调节树突状细胞与T细胞间的信号传递、参与树突状细胞的抗原俘获等方面具有重要的生物学意义。其中ILT2、ILT3、ILT4属抑制性受体,其结构共同特点是有一个长的膜内段,含有3个免疫受体酪氨酸抑制基序,有4个或2个膜外的IgSF区。该类因子的功能主要是抑制分子,但其在肿瘤细胞上的表达和功能尚不清楚。
HLA-G分子是一种非经典HLA-I类抗原,该基因具有8个外显子和7个内含子。HLA-G分子在结构上胞内段很短,并且原始的HLA-G转录产物经选择性剪切产生7种mRNA,编码出7种HLA-G蛋白异构体。其中HLA-G1和HLA-G5可以高特异性结合ILT2、ILT4,且与ILT2、LT4结合亲和力比经典HLA-I与ILT2, ILT4亲和大3-4倍。HLA-G分子通过抑制免疫活性细胞的功能在免疫耐受的建立和维持中发挥关键作用。HLA-G可通过与NK细胞、T细胞、APC等细胞表面的抑制性受体ILT-2、ILT-4等结合发挥抑制性免疫调节作用。可溶性HLA-G(sHLA-G)还可与CD8+细胞受体结合,诱导NK细胞和T细胞的凋亡、抑制同种特异性T细胞的细胞周期进程。除此之外,研究显示,HLA-G还可诱导调节性T细胞和抑制性NK细胞的产生,并可在很大程度上通过移植细胞颗粒极化来保护靶细胞不被NK细胞和T细胞杀伤。HLA-G分子除表达于胎盘绒毛膜细胞、肿瘤细胞外,还可少量表达在众多组织细胞上,包括T淋巴细胞。而胃癌患者中淋巴细胞HLA-G表达变化如何?作为抑制性受体ILT2、ILT4等的主要配体,在不同分化程度胃癌发生过程中所起作用如何,目前尚不清晰。
研究目的和方法：
一、本研究采用实时荧光定量PCR-Sybr Green I和FACS流式细胞术等方法对人的高分化胃癌细胞株(MKN1)、中分化胃癌细胞株(SGC-7901、AGS)、低分化胃癌细胞株(MGC803)和未分化分化胃癌细胞株(HGC-27、BCG823)中的mRNA和蛋白表达进行了检测和分析,系统地探讨了ILT2、ILT3和ILT4在不同分化程度的人胃癌细胞中的表达变化,为后期试验和相关研究提供了试验依据。
二、为了探讨不同表达程度的抑制性受体ILTs对免疫细胞的影响,我们通过体外细胞试验,将ILT2lowILT3lowILT4low胃癌细胞MKNI和ILT2highILT3highILT4high胃癌细胞HGC-27分别与PBMC和NK细胞共培养,通过检测细胞杀伤活性(MTT),CD4+、CD8+T淋巴细胞和NK细胞上HLA-G分子的表达改变探讨抑制性受体ILTs对效应细胞的调控作用。
三、为进一步探讨抑制性受体ILT2、ILT3和ILT4在临床应用中的价值,采用免疫组织化学方法检测了临床不同分化程度胃癌患者病理组织中ILT2、ILT3和ILT4的表达,并探讨了其与肿瘤生物学行为和临床特征的关系。
四、为了探讨作为抑制性受体ILTs主要配体的HLA-G在临床胃癌患者淋巴细胞中的表达变化,应用TaqMan探针FQ-PCR和FACS流式细胞术对不同分化胃癌患者外周血淋巴细胞HLA-G mRNA和CD4+、CD8+T淋巴细胞上HLA-G分子表达及其与临床进程的关系进行了初步分析。
以上研究通过体外细胞试验和临床应用研究,系统的探讨了抑制性受体ILT2、ILT3和ILT4在不同分化程度的胃癌细胞中的表达变化及其对效应细胞的影响,期望为阐明胃癌发生和转移的分子机制提供实验依据,同时为临床胃癌的诊断、防治和新药开发寻找新的靶目标提供依据。
结果及结论：
一、胃癌细胞株抑制性受体ILTs mRNA和蛋白表达
1.实时荧光定量PCR-Sybr Green I检测结果表明,6株不同分化程度的人胃癌细胞均不同程度表达了ILT2、ILT3和ILT4 mRNA,尤以ILT2表达最强。其中在高分化的胃癌细胞株MKN1中ILT2、ILT3和ILT4 mRNA表达最低,未分化胃癌细胞株HGC-27和BCG823的mRNA表达最高,显示随分化程度存在显著性差异。
2.FACS流式细胞术检测显示,6株胃癌细胞中除一株未分化胃癌细胞BCG823表达ILT3、ILT4极低外,其余均检测到ILT2、ILT3和ILT4不同程度的蛋白表达,且其表达程度与肿瘤细胞分化相关,尤以ILT2表现最明显。
上述实验结果表明,通过某种共同信号途径使恶性程度高的胃癌细胞高表达抑制性受体ILT2、ILT3和ILT4,并可能影响到效应细胞的功能及对肿瘤的杀伤。
二、抑制性受体ILTs对效应细胞调控的实验研究
1.ILT2highILT3highILT4high胃癌细胞HGC-27与PBMC、NK细胞共培养后效应细胞杀伤活性(MTT)较ILT2lowILT3lowILT4low胃癌细胞MKN1与PBMC、NK细胞共培养后效应细胞杀伤活性显著降低,初步表明胃癌细胞不同表达程度的ILT2、ILT3、ILT4影响PBMC、NK细胞的增殖和杀伤作用。
2.ILT2highILT3highILT4high的HGC-27细胞和ILT2lowILT3lowILT4low的MKNl细胞分别与PBMC和NK细胞共培养24h后,与各自对照相比,T细胞和NK细胞表面HLA-G的表达明显变化,且ILT2highILT3highILT4high的HGC-27细胞对HLA-G的影响较ILT2lowILT3lowILT4low的MKN1细胞更明显。其中T淋巴细胞HLA-G主要表达于CD4+T细胞,CD8+T细胞表达很低或基本不表达；CD56+NK细胞表达结果显示同样的趋势,但总体表达水平较CD4+细胞低。
实验结果提示胃癌细胞上ILT2、ILT3和ILT4分子表达对效应细胞的杀伤活性有影响,并可能对HLA-G的表达有一定的调控作用。
三、胃癌患者ILT表达的临床应用研究
免疫组织化学分析显示,50例不同组织类型、不同分化程度的胃癌患者病理组织中ILT2、ILT3和ILT4分子有不同程度的表达。在肿瘤细胞上的表达形式是散在的,可位于胃癌细胞膜或胞浆内或两者皆有,病灶周围的基质细胞也有部分表达。ILT2、ILT3和ILT4表达阳性率在50例胃癌组织标本中差异较大。其中ILT2表达阳性率最高,为62.0%(31/50),ILT3、ILT4表达阳性率分别为18.0%(9/50)和34%(17/50),正常胃组织中未见ITL2,ILT3, ILT 4的表达。提示抑制性受体ILTs,尤其是ILT2有可能成为胃癌临床诊断的有价值指标,并为胃癌临床干预治疗提供新的靶点。
四、胃癌患者淋巴细胞非经典HLA-G的表达
1.通过TaqMan探针FQ-PCR检测发现,胃癌患者及健康对照淋巴细胞HLA-G mRNA,总体表达水平较弱。其中,胃癌临床分级Ⅰ+Ⅱ期的患者与健康对照相比相对表达量无显著性差异(P>0.05)；临床分级Ⅲ+Ⅳ期患者转录水平较Ⅰ+Ⅱ期相对表达量低(P<0.05)。而从临床病理组织分化程度分析,分化良好型与低分化型胃癌患者HLA-G mRNA表达未见明显改变。
2.通过FACS流式细胞仪检测发现,无论健康对照和胃癌患者,淋巴细胞HLA-G分子表达阳性率均较低。与同型对照相比,CD8+T细胞基本不表达,HLA-G分子表达主要集中于CD4+T淋巴细胞,且表达阳性率在不同胃癌患者中变化幅度较大,可能与肿瘤微环境及相关影响有关。
Background:
Gastric Cancer is one of the most frequent malignant tumors which are harmful to human health.There are more than 9.3 million newly discovered cases annually in the world. The death rate of Gastric Cancer is approximately 29.34 per million (man 40.80 per million and woman 18.60 per million respectively) that is second larger in the world. According to Ministry of Health statistics in 2006, the number of Gastric Cancer patients is as many as 4 million, and 3 million people die of this disease every year in our country. Recently many scholars study the cause and diversion of Gastric Cancer and acquire some success. However, we are still in double regarding the mechanism of cancer, early diagnosis and estimate of prognostic. Thus, it is significant to research the mechanism of cancer and to discuss the state and function of immunocyte during the process of tumor. There is no doubt that it will be beneficial to understand and cure Gastric Cancer.
At present, the pathogen of this cancer is not clear. Epidemiology research suggests the cause of Gastric Cancer relates to many factors such as food, infection and inheritance. Recently, it is considered that the process of Gastric Cancer is an interaction between immune system and cancer cells in host. It involves not only change of effector cell functions (abnormal quantity and function of T lymphocyte) and some cytokines (IFN-y and IL-10), but also the abnormal tumor cell self (high expression of FasL and lack of co-stimulatory molecules and decrease of MHC) and relevant oncogene and anti-oncogene modification. Among all the factors above, the lack of co-stimulatory molecules which are expressed on the cancer cell surface is one of the most important reasons that results in immune evasion. Positive stimulatory molecules influence activation and proliferation of T lymphocyte while negative ones inhibit the function of T lymphocyte through the follow two ways:they induce inhibitory factors to express on effect cells and tumor cells.
Ig-like transcript (ILT) which is also called leukocyte inhibitory receptor(LIR) is a kind of newly discovered receptor family which recognize HLA-I. At present,9 members of the ILT family are known and they are expresses on a wide range of cells which include T lymphocyte, monocyte, NK and dendrite cells. Different kinds of ILTs play a great role in immunologic modification by transmitting inhibitory or simulative signals, for instance, in term of inhibiting activity of killer cells and regulating signal transmission between dendrite cells and T lymphocytes and so on. Inhibitory receptors (ILT2, ILT3, ILT4) consist 4 or 2 extracellular C-2 type Ig-SF domains and possess long cytoplasm tails that contain 3 immunoreceptor tyrosine-based inhibitory motifs (ITIMs). However, the expression and function of these receptors have not been well understood on tumors.
HLA-G molecule is one kind of nonclassical antigen and possesses a shore cytoplasm domain. HLA-G gene contains 8 extrons and 7 introns. Alternative splicing of the primary transcripts results in seven different mRNA, encoding four membrane-anchored (HLA-G1,G2,G3,G4) and three soluble (HLA-G5,G6,G7) isoforms, in which HLA-G 1 and HLA-G5 can combine ILT2 and ILT4 with high specificity. HLA-G plays an important part in establishing and maintaining immune tolerance by inhibiting the function of immune cells. HLA-G molecule exerts suppressive role via integrating with ILT2 and ILT4 which be expressed in NK cells, T lymphocytes and APC. Soluble HLA-G(sHLA-G) molecule also can link cells receptor with CD8+thus induces apoptosis of NK and T lymphocytes. Besides, the latest research suggests that HLA-G molecule can tempt the produce of Tregs and inhibitory NK cells, and protect the target cells from being damaged by NK and T lymphocytes to a large extent. HLA-G molecule can be primarily expressed on the surface of trophoblast cells and cancer cells. There are also a few HLA-G molecules which can be expressed on the surface of histiocytes, such as T lymphocyte. However, we are still wondering in the variety of HLA-G on T lymphocytes of patients with Gastric Cancer, which is main ligand for inhibitory receptor ILT2 and ILT4.
Objectives and Methods:
Ⅰ. We analyzed the mRNA and protein expression of well-differentiated Gastric Cancer cell lines (MKN1), moderate differentiation Gastric Cancer cell lines (SGC-7901、AGS), poorly differentiated cell lines(MGC803) and undifferentiation cell lines (HGC-27、BCG823) respectively by fluorescent quantization PCR-Sybr GreenⅠand FACS flow cytometer. And we discussed the variety of ILT2, ILT3, ILT4 in diverse differentiation of Gastric Cancer cell lines systemically, which provide experimental evidence for succedent research.
Ⅱ. In order to explore the effect of the different degree expression of inhibiting ILTs to immune cells, we try to investigate that different leveles of inhibitory ILTs influence immunocytes in vitro. We cultureed well-differentiated Gastric Cancer cell lines (MKN1), which express slight ILT2/ILT3/ILT4, and undifferentiation Gastric Cancer cell lines (HGC-27), which express substantial ILT2/ILT3/ILT4, with PBMC and NK together respectively, and tested MTT and HLA-G in CD4+、CD8+T lymphocytes and NK to discuss the role that inhibitory ILT regulate effector cells.
Ⅲ. Immunohistochemistry was used to detect the expression of ILT2/ILT3/ILT4 in pathologic tissue with diverse differentiation from patients who surfer Gastric Cancer to make further efforts to explore the value of ILT2/ILT3/ILT4 in clinical application.
Ⅳ. We also introduced TaqMan probe FQ-PCR and FACS flow cytometer to inspect the expression of HLA-G that is ligand for ILTs in PBMC and CD4+、CD8+T lymphocyte, and to research the changes of HLA-G and analyse the relation between Gastric Cancer phase and the expression of HLA-G molecule preliminarily.
In a word, from this part of research we discussed systemically the variety of ILT2, 3,4 in diverse differentiation of Gastric Cancer cell lines and their effect on immunocytes. It is expected to provide experimental evidence to illustrate the mechanism for the growth and metastasis of tumor and theoretical basis simultaneously for the diagnosis and treatment of Gastric Cancer and the exploiture of new drugs.
Results and Conclusions:
I. Expression of inhibitory ILTs mRNA and protein of human gastric cancer:an experiment study in vitro
1. Using fluorescent quantization PCR-Sybr Green I, we detected the expression of ILT2,3,4 mRNA from 6 Gastric Cancer cell lines with diverse differentiation. From the results, we can see that all the differentiation groups express various extents ILT mRNA, and ILT2 mRNA is expressed the highest especially. In the mean time, well-differentiated Gastric Cancer cell lines (MKN1) express the lowest amount of ILTs among them and, on the contrary, undifferentiation Gastric Cancer cell lines (HGC-27 and BCG823) express the highest amount of ILTs. There is significant difference in 6 cell lines with diverse differentiation.
2. We found that ILT2,3,4 are expressed with different extent in nearly all differentiation groups except undifferentiation Gastric Cancer cell lines (BCG823), which express little ILT3 and ILT4, and the different levels of ILTs relates to the differentiation of tumor cells by FACS flow cytometer.
Experimental results above demonstrate that malignant Gastric Cancer cells can express ILT2/ILT3/ILT4 through some common pathway, which influence the function of effector cells and their killer activity to tumor cells.
II Inhibitory ILTs regulation to effector cells:an experiment study in vitro
l.By coculture ILT2highILT3highILT4high HGC-27 cell and ILT2lowILT3lowILT4low MKN1 cell with PBMC、NK respectively, we found that the killer activity of effector cells was reduced distinctly, and the former was more prominence than latter. Thus, we considered that varying degree of ILT2/ILT3/ILT4 that were expressed by human stomach cancer cell influences the proliferation and killer activity of PBMC and NK cells.
2. Coculture were obtained as described above for 24 hours, we conclued that HLA-G at the surface of T. and NK cells varies markedly and ILT2highILT3highILT4hig HGC-27 had a more significant effect on HLA-G than those by ILT2lowILT3lowILT4low MKN1. Inaddition, HLA-G that is expressed at the surface of T lymphocytes mainly located CD4+T lymphocytes, and there was little even no HLA-G at the surface of CD8+T lymphocytes. Besides, HLA-G expressed on CD56+NK cells is lower than that in T lymphocytes.
Experimental results indicated that ILT2/ILT3/ILT4 have an impact on the killer activity of effector cells, and may regulate the expression of HLA-G..
III. Expression of inhibitory ILTs on gastric cancers:a clinical study
The expression of ILT2/ILT3/ILT4 from 50 Gastric Cancer pathological tissues were tested. From the results, we can see that it is dissimilar with diverse differentiation and type of tumor, and ILT2/ILT3/ILT4 cound be expressed either in cytoplasm or membrane of Gastric Cancer cells and even both. The positive rate of ILT2,ILT3 and ILT4 expression among 50 Gastric Cancer pathological tissues also varies a lot, and the positive rate of ILT2 is the highest-62.0%(31/50), while the positive rate of ILT3 and ILT4 is 18.0%(9/50) and 34%(17/50) respectively. There was no ILT2/ILT3/ILT4 on normal tissues, which indicated that inhibitory ILTs, especially ILT2, may be a valuable index for diagnosing Gastric Cancer and provide a new target to treat gastric cancer.
IV. Expression of non-classical HLA-G on PBLs of gastric cancers:a clinical study
1. By Fluorescent quantitation RT-PCR, we considered that HLA-G mRNA in both lymphocytes from Gastric Cancer and healthy control was weak, and there was no significant difference betweenⅠ+ⅡGastric Cancer and healthy control (P>0.05) However, HLA-G mRNA inⅢ+ⅣGastric Cancer was lower than that inⅠ+Ⅱ(P< 0.05). Also, there is no distinct change between well-differentiated and poorly differentiated Gastric Cancer in term of clinical differentiation.
2. By FACS Flow Cytometry, we found that the expression of HLA-G on lymphocytes both from Gastric Cancer and healthy control was low, and there was nearly no HLA-G expression on CD8+T lymphocytes of patients of Gastric Cancer. On the contrary, HLA-G molecules were mainly expressed on CD4+T lymphocytes, and the positive rate was also different in diverse patients, which was associated with tumor microenvironment and other influence factor.
引文
l.Crew KD, Neugut AI. Epidemiology of gastric cancer [J]. World J Gast roenterol, 2006,12 (3):3542362.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002[J]. CA ancer J Clin,2005,55(2):742108.
3. Oht su A, Yoshida S, Saijo N,et al. Disparities in gast ric cancer chemotherapy between the East and West [J]. J Clin Oncol,2006,24 (14):2188.
4. Hiromichi Kawaida, Koji Kono, Akihiro Takahashi. et al. Distribution of CD4(+) CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. Journal of Surgical Research,2005,124,:151-157
5. Toni Aebischer, Bernadette Lucas, Jan Koesling. et al. How CD4+T cells may eliminate extracellular gastric Helicobacter? Journal of Biotechnology,2000,83: 77-84
6. Katsuiku Hirokawa, Masanori Utsuyama, Toshiaki Ishikawa. et al. Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mechanisms of Ageing and Development.2009,130:86-91
7. Calin Stoicov, Reza Saffari, Xun Cai.et al. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma:bacterial and host factors responsible for altered growth signaling. Gene,341,27:1-17
8. C. A. Schmitt, W. Schwaeble, B. M. Wittig. et al. Expression and regulation by interferon-y of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. European Journal of Cancer,1999,35: 117-124
9. Hinrich Abken, Andreas Hombach, Claudia Heuser, et al. Tuning tumor-specific T-cell activation:a matter of costimulation? Trends in Immunology,2002,23: 240-245.
10. Ninke Leffers, Annechien J.A. Lambeck, et al. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecologic Oncology,2008,10:365-373.
11. Nick Kassouf, Martin H. Thornhill. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-a, to induce apoptosis in Jurkat T cells:Possible mechanisms for immune escape by head and neck cancers. Oral Oncology,2008, 44:672-682.
12. Eleftherios P. Diamandis. Clinical applications of tumor suppressor genes and oncogenes in cancer. Clinica Chimica Acta,1997,257:157-180
13. Tomoko Amachika, Daisuke Kobayashi, Ryosuke Moriai, et al. Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer,2007,56:337-340
14. Martin Loos, Nathalia A. Giese, Jorg Kleeff, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Letters,2008,268:98-109
15. John K. Petty, Ken He, Christopher L.et al. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). The American Journal of Surgery,2002,183:512-518
16. K.H. Haraldsdottir, K. Ivarsson, S. Gotberg, et al. Interstitial laser thermotherapy (ILT) of breast cancer. European Journal of Surgical Oncology,2008,34:739-745
17. Stefanie Gross, Peter Walden. Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer. Immunology Letters,2008,116:7-14
18. George Vlad, Raffaello Cortesini, Nicole Suciu-Foca. CD8+T suppressor cells and the ILT3 master switch. Human Immunology,2008,69:681-686
19. Leonie S. Taams, Jocea M.R. van Amelsfort, Machteld M. Tiemessen. et al. Modulation of monocyte/macrophage function by human CD4+CD25+regulatory T cells. Human Immunology,2005,66:222-230
20. Lefebvre S, Antoine M, Uzan S,et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol.2002,196(3):266-74.
21. Favier B, Lemaoult J, Lesport E. et al. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J.2010;24(3):689-99.
22. Yuping Sun, Jie Liu, Ping Gao, et al. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest,2008,134: 783-788
23.Van der Slik AR,Koeleman BP,Verduijn W.KIRS intype 1 diabetes:disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects.Diabetes,2003,52(10):2639-2645.
24.Nishimura H,Minato N,Nakano T.Immunological studies on PD-1-deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int.Immunol, 1998,10:1563-1568
25.Nishimura H,Nose M,Hiai H.Development of lupus-like autoimmune diseases by disruption of the PD-1gene encoding an ITIM motif-carrying immuno-receptor. Immunity,1999,11:141-145
26. Liang Shan, Qifeng Yang, Misa Nakamura, et al. Active Allele Loss of the Androgen Receptor Gene Contributes to Loss of Androgen Receptor Expression in Female Breast Cancers. Biochemical and Biophysical Research Communications, 2000,275:488-492
27. M. Maynadier, J.M. Ramirez, A.M. Cathiard, N, et al. Inhibitory effects of unliganded estrogen receptor alpha on breast cancer cell growth and invasion. European Journal of Cancer Supplements,2008,6:22
28. K Detjen, M C Fenrich, C D Logsdon. Transfected cholecystokinin receptors mediate growth inhibitory effects on human pancreatic cancer cell lines. Gastroenterology,1997,112:952-959
29. Alison Crawford, E John Wherry. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Current Opinion in Immunology,2009,21:179-186
30. Boris Fedoric, Ravi Krishnan. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunology Letters,2008, 120:49-56
31. Abderrahim Naji, Antoine Durrbach, Edgardo D. Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways. Human Immunology,2007,68(4):233-239.
32. Christian A. Gleissner, Thomas J. Dengler. Induction of ILT expression on nonprofessional antigen presenting cells:Clinical applications. Human Immunology,2009,70(5):357-359.
33. C Gleissner, A Zastrow, R Klingenberg, N Xia, T.J Dengler. IL-10 induces suppressor of cytokine secretion-3 (SOCS-3) and ILT-3 in human endothelial cells and inhibits T cell costimulation. The Journal of Heart and Lung Transplantation, Volume 22, Issue 1, Supplement 1, January 2003, Page S81
34. Abderrahim Naji, Antoine Durrbach, Edgardo D. Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways. Human Immunology,2007,68(4): 233-239.
35. A. Monsivais-Urenda, P. Nino-Moreno, C. Abud-Mendoza. Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). Journal of Autoimmunity,2007,29:97-105
36. Idan Tamir, Joseph M Dal Porto, John C Cambier. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2:regulators of B cell signal transduction. Current Opinion in Immunology,2000,12(3):307-315.
37. Chengyu Wu, Mingzhong Sun, Lijun Liu, G. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene,2003,306(13):1-12.
38. Jinyi Zhang, Ally-Khan Somani, Katherine A. Siminovitch. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Seminars in Immunology,2000,12(4):361-378
39. Toshio Inoue, Yoshihiro Suzuki, Kazuya Mizuno, et al. SHP-1 exhibits a pro-apoptotic function in antigen-stimulated mast cells:Positive regulation of mitochondrial death pathways and negative regulation of survival signaling pathways. Molecular Immunology,2009,47:222-232
40. Samaridis J, Colonna M_1997.Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells:structural evidence for new stimulatory and inhibitory pathways. Eur J Immunol 27:660-665
41. Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, Colonna M_1997. A novel inhibitory receptor ILT3. expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185:1743-1751
42. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity,1997,7:273-282.
43. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, L'opez-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med.1997,186:1809-1818
44. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol.1998,160:3096-3100
45. Fanger NA, Cosman D, Peterson L, Braddy SC, Maliszewski CR, Borges L. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol.1998,28:3423-3434
46. Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor ILTl.that associates with Fc receptor gamma-chain. J Immunol.1999,162:5-8
47. Xin-Sheng Ju, Christine Hacker, Barbara Scherer, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene,2004,31:159-164
48. Yasuo Shirakihara, Linda Rasubala, P. Anton van der Merwe, et al. Entropically Driven MHC Class I Recognition by Human Inhibitory Receptor Leukocyte Ig-like Receptor B1 (LILRB1/ILT2/CD85j). Journal of Molecular Biology,2006, 55:237-248
49. Tara L. Chapman, Astrid P. Heikema, et al. Crystal Structure and Ligand Binding Properties of the D1D2 Region of the Inhibitory Receptor LIR-1 (ILT2). Immunity, 2000,13:727-736
50. Paula Bonorino, Muhammad Ramzan, Xavier Camous, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. Journal of Hepatology,2009,51:458-467
51. Miguel Lopez-Botet, Manuel Llano, Francisco Navarro, et al. NK cell recognition of non-classical HLA class I molecules. Seminars in Immunology,2000, 12:109-119
52. L.M.A. Balderas-Pena, S.D. Toro-Arreola, T. Garcia-Iglesias, et al. Placental expression of HLA-G, and its correlation with ILT2 expression on surface of CD4+ T lymphocytes and NK cells in preeclamptic women. Journal of Reproductive Immunology,2006,71:170-171
53. Claudia S. Wagner, Alexander Rolle, et al. Structural Elements Underlying the High Binding Affinity of Human Cytomegalovirus UL18 to Leukocyte Immunoglobulin-like Receptor-1. Journal of Molecular Biology,2007, 373(3):695-705
54. Yong Chen, Feng Gao, Fuliang Chu, et al. Crystal Structure of Myeloid Cell Activating Receptor Leukocyte Ig-like Receptor A2 (LILRA2/ILT1/LIR-7) Domain Swapped Dimer:Molecular Basis for Its Non-binding to MHC Complexes. Journal of Molecular Biology,2009,386:841-853
55. George Vlad, Zhuoru Liu, Qing-Yin Zhang, et al. Immunosuppressive activity of recombinant ILT3. International Immunopharmacology,2006,4:1889-1894
56. Nicole Suciu-Foca, Raffaello Cortesini. Central role of ILT3 in the T suppressor cell cascade. Cellular Immunology,2007,248:59-67
57. John S. Manavalan, Paola C. Rossi, George Vlad, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transplant Immunology, 2003,11:245-258
58. John S. Manavalan, George Vlad, Seunghee Kim-Shulze, et al. Generation of tolerogenic antigen presenting cells:crucial role of inhibitory receptors ILT3 and ILT4. Human Immunology,2003,64:S21
59. Adriana I. Colovai, Lawrence Tsao, Hana Lin, et al.21-OR:Expression of inhibitory receptors ILT3 and ILT4 on neoplastic B cells from patients with high-risk chronic lymphocytic leukemia:Implications for allogeneic stem cell transplantation. Human Immunology,2007,68:S111
60. ColonnaM, H.Nakajima, and M. Cella. Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. J Leukoc Biol,1999; 66:718.
61.Colonna M, J Smaaridis, M Cella, etal. Human myelomonocytic cells express an Inhibitory receptor for classic and nonclassic MHCI classic molecues. J Immunol, 1998;160:3096.
62.ColonnaM, H.Nakajima, and M.Cella.A family of inhibitory and activating Ig-like receptors that modulate founction of lymphoid and myeloid cells.Semin Immunol, 2002;12:121.
63.Raveteh JV, and LL.Lnaier. Immune inhibitory receptors. Science.2000,290: 84.
64. Allan.DS, M Colonna, LL. Lanier, etal. Tetrameric complexes of human Histocompatibility leukoeyt antigen (HLA)-G bind to peripheral blood myelomonocytic cells J ExP Med.1999;189:1149.
65.Allan DS, EJ Lepin, VM Braud, et al. Tetrameric comples of HLA-E, HLA-F and HLA-G..J Immunol-Methods.2002,268:43
66.Allen RL, T Raine, A Haude, et al. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol,2001,167:5543
67.Lepin EJ, JM Bastin, DS Allan, et al. Functional characterization of HLA-F and binding of HLA-F terramers to ILT2 and ILT4 receptors. Eur J immunol.2000, 30:3552
68. Young NT, FC anvaez,; M Uhrberg, et al.Conserved organization of the ITL/LIR Gene family within the Polymoprhic human leukoeyte receptor complex. Immunogeneties,2001,53:270.
69. Homfeister,V and EH Weiss. HLA-G modulates immune responses by diverse receptor interactions.Semin Cancer Biol,2003,13:317.
70.Shiroishi M, K Tsumoto, K Amno, et al. Human inhibitory receptors Ig-like transcriptor 2(ILT2) and ILT4 compete with CD8 for MHC-class I binding and bind preferentially to HLA-G. Natl Acad Sci USA,2003,100:8856
71. Marco Colonna, Hideo Nakajima, Marina Cella. A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Seminars in Immunology.2000,12:121-127.
72. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol.2000,48(1):17-26.
73. Claudia S. Wagner, Alexander Rolle, David Cosman, et al. Structural Elements Underlying the High Binding Affinity of Human Cytomegalovirus UL18 to Leukocyte Immunoglobulin-like Receptor-1. Journal of Molecular Biology,2007, 373(3):695-705
74. Bo Dupont, Katharine C Hsu. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Current Opinion in Immunology,2004,16(5):634-643.
75. Idan Tamir, Joseph M Dal Porto, John C Cambier. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2:regulators of B cell signal transduction. Current Opinion in Immunology,2000,12(3):307-315.
76. Sabek O, Dorak MT, Kotb M, Gaber AO, Gaber L. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation.2002,74(5):701-7.
77. Roge R, Thorsen J, Toning C, Ozbay A, Moller BK, Carstens J. Commonly used reference genes are actively regulated in in vitro stimulated lymphocytes. Scand J Immunol.2007,65(2):202-9.
1. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance inpregnancy. FASEB J,2005,19:681-93.
2. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. nnuRev Immunol.2003,21:685-711.
3.Moseman EA, Liang X, Dawson AJ, etal. Human plasmacytoid dendritic cells activated by CpG oligo deoxynucleotidesinduce the generation of CD4+CD25+
regulatory T cells. J Immunol,2004; 173:4433-42.
4. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, et al.Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by humandendritic cells and down-regulated following activation. Gene,2004; 331: 159-64.
5. Suciu-Foca N, Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 2007;248:59-67.
6. A. Monsiva'is-Urenda, P. Ni-no-Moreno, C. Abud-Mendoza, et al. Analysis of expression and function of the inhibitory receptor ILT2 in peripheral blood mononuclear cells frompatients with systemic lupus erythematosus (SLE). Journal of Autoimmunity,2007,29:97-105.
7. M.J. Benito, M. Lopez-Hoyos, G. Fernandez-Fresnedo, Changes in the Expression of the Immunoglobulin-like Transcript 3(ILT3) and ILT4 Receptors in Renal Allograft Recipients:Effect of Donor and Recipient Aging. Transplantation Proceedings,2008,40:2894-2896.
8. Valeska Hofmeister, Elisabeth H. Weiss. HLA-G modulates immune responses by diverse receptor interactions. Seminars in Cancer Biology,2003,13:317-323.
9. Xin-Sheng Ju, Christine Hacker, Barbara Scherer, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene,2004,31:159-164.
10. ColonnaM, H.Nakajima, and M.Cella.A family of inhibitory and activating Ig-like receptors that modulate founction of lymphoid and myeloid cells.Semin Immunol, 2002;12:121.
11. Allan.DS, M Colonna, LL. Lanier, etal. Tetrameric complexes of human Histocompatibility leukoeyt antigen(HLA)-G bind to peripheral blood myelomonocytic cells .J ExP Med,1999;189:1149.
12. Yuping Sun, Jie Liu, Ping Gao, et al. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest,2008,134:783-788.
13.Neel Sengupta, Tammie S. MacFie, Thomas T. MacDonald, et al. Cancer immunoediting and "spontaneous" tumor regression. Pathology-Research and Practice,2010,206(1):1-8.
14. Sophie Lefebvre, Francisco Adrian, Philippe Moreau, et al. Modulation of HLA-G expression in human thymic and amniotic epithelial cells. Human Immunology, Ⅴ 2000,61(11):1095-1101.
15. Joel LeMaoult, Nathalie Rouas-Freiss, Edgardo D. Carosella. Immuno-tolerogenic functions of HLA-G:Relevance in transplantation and oncology. Autoimmunity Reviews,2005,4(8):503-509.
16.Jes Dietrich, Hideo Nanajima, Marco Colonna. Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells. Microbe and infection.2000,2:323-329.
17. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science.2000,6:290 (5489):84-9.
18. Samaridis J, Colonna M. Cloning of novel immunoglobulin super family receptors expressed on human myeloid and lymphoid cells:structural evidence for new stimulator yand inhibitory pathways. Eur J Immunol,1997,27:660-665.
19. Wende H, Colonna M, Ziegler A, Volz A. Organization of the leukocyte receptor cluster LRC on human chromosome19q13.4. Mamm Genome,1999,10:154-160
20. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class Ⅰ molecules. J Immunol 1998;160:3096-3100.
21. Vlad G, Cortesini R, Suciu-Foca N. CD8+T suppressor cells and the ILT3master switch. Hum Immunol 2008;69:681-6.
22. Cortesini R, Suciu-Foca N. ILT3+ ILT4+ tolerogenic endothelial cells in transplantation. Transplantation,2006;82:S30-2.
23. Colonna M, Nakajima H, Navarro F, Lopez-Botet M. A novel family of Ig-likereceptors for HLA class I molecules that modulate function of lymphoid andmyeloid cells. J Leukoc Biol 1999;66:375-81.
24. C.-C. Chang, N. Oberfield, P. Satwani, et al. Differential gene expression profiles of the CD4+CD25+ T suppressor (Ts) cell population in human cord blood and adult peripheral blood vs murine spleen cells. Biology of Blood and Marrow Transplantation,2004,10(1):46.
25. John S. Manavalan, Paola C. Rossi, George Vlad, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transplant Immunology, 2003,11(3-4):245-258.
26.Juan Wu and Anatolij Horuzsko. Expression and function of immunoglobin-like transcripts on tolerogenic dendritic cells. Human Immunology.2009,70:353-356
27. Manavalan JS, Rossi PC, Vlad G, Piazza F, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol,2003, 11:245-58.
28. Vlad G, Cortesini R, Suciu-Foca N. CD8+ T suppressor cells and the ILT3master switch. Hum Immunol,2008;69:681-6.
29. Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, et al. Tolerization of dendritic cells by T(S) cells:The crucial role of inhibitoryreceptors ILT3 and ILT4. Nat Immunol.2002;3:237-43.
30. Pavlina Braunfuchsova, Ji Salat, Jan Kopecky. CD8+ T lymphocytes protect SCID mice against Encephalitozoon cuniculi infection. International Journal for Parasitology,2001,31(7):681-686.
31.Tsufit Gonen-Gross and Ofer Mandelboim. HLA-G Complexes Are Observed on the Cell Surface. Human Immunology.2007,68:227-232.
32. Christine Guillard, In'es Zidi, Celine Marcou, et al. Role of HLA-G in innate immunity through direct activation of NF-κB in natural killer cells. Molecular Immunology.2008,45:419-427.
33. Meike Mitsdoerffe, Bettina Schreiner, Bernd C. Kieseier, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-h in vitro and in vivo:rationale for the therapy of multiple sclerosis. Journal of Neuroimmunology 159 (2005) 155-164.
34. LeMaoult J, K Zafranloo, C Le Danff, et al. HLA-G up-regulates ILT2,ILT3ILT4, and KIR2DL4 in antigen presenting cells, NK cells and T cells. Faseb J,2005, 19:662.
35.Nakajima H, A Asai, A Okada, et al. Transcriptional regulation of ILT family receptors. J Immunol.2003,171:6611.
36. Pedersen AE, M Gad, MR Walter, et al. Induction of regulatory dendritic cells by dexamethasone and lalPha,25-Dihydroxy vitaminD(3). Immunol. Lett,2004: 91:63.
37. Papanikolaou NA, ER Vasileseu and N Suciu-Foca. Novel single nucleotide Polymorphisms in the human immune inhibitory immunoglobulin-like T cell receptor type4. Hum Immunol,200,65:700.
38. Hofmeister V, and EH Weiss. HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol.2003,13:317.
39. Shiroishi M, K Tsumoto, K Amano, et al. Human inhibitory receptors Ig-like transcript 2(ILT2) and ILT4 Compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Pro Natl Acad Sci USA.2003,100:8856.
40. Vasiliki Drossou-Agakidou, Florence Kanakoudi-Tsakalidou, Kosmas Sarafidis,,et al. In vivo effect of rhGM-CSF and rhG-CSF on monocyte HLA-DR expression of septic neonates. Cytokine,2002,18(5):260-265.
41. Kazunori Nakase, Kenkichi Kita, Hiroshi Anazawa, et al. Induction of interleukin-2 receptor alpha chain expression on immature acute myelocytic leukemia cells. Leukemia Research,1994,18(4):269-274
42. Sophie Lefebvre, Philippe Moreau, Virginie Guiard, et al. Molecular mechanisms controlling constitutive and IFN-y-inducible HLA-G expression in various cell. types. Journal of Reproductive Immunology,1999,43(2):213-224
43. Joel LeMaoult, Kamelia Zafaranloo, Caroline. Le Danff and Edgardo D. Carosella. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. The FASEB Journal.2005;19:662-664.
44.Abderrahim Naji, Antoine Durrbach, Edgardo D. Carosella, Nathalie Rouas-Freiss. Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways. Human Immunology,2007,68(4):233-239.
45. Philippe Rousseau, Magali Le Discorde, Gael Mouillot, et al. The 14 bp Deletion-Insertion polymorphism in the 3'UT region of the HLA-G gene influences HLA-G mRNA stability. Human Immunology,2003,64(11):1005-1010.
46. Vera Rebmann, Jens Regel, Dietmar Stolke, Hans Grosse-Wilde. Secretion of sHLA-G molecules in malignancies. Seminars in Cancer Biology,2003,13(5): 371-377.
47.Rabbani H, Schedvins K, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism[J]. J Clin Invest.2002,110:1515-1523.
48. Iman Khalil-Daher, Beatrice Riteau, Catherine Menier,et al. Role of HLA-G versus HLA-E on NK function:HLA-G is able to inhibit NK cytolysis by itself. Journal of Reproductive Immunology,1999,43(2):175-182
49. Sheshgiri R, Rao V, Tumiati LC, Xiao R, Prodger JL, Badiwala M, et al. Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells. Circulation.2008,118(14 Suppl):58-64.
50. Yie SM, Li LH, Li GM, Xiao R, Librach CL. Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum Reprod.2006,21(1):46-51.
51. Moreau P, Faure O, Lefebvre S, Ibrahim EC, O BM, Gourand L, et al. Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. Transplant Proc.2001,33(3):2277-80.
52. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr.2007,13(4-5):217-26.
53. Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo:rationale for the therapy of multiple sclerosis. J Neuroimmunol.2005,159(1-2):155-64.
54. Ugurel S, Rebmann V, Tilgen W, Grosse-Wilde H, Reinhold U. High serum levels of sHLA-G in melanoma patients induced by interferon-alpha therapy. J Invest Dermatol.2000,114(4):835.
55. Bamberger AM, Jenatschke S, Schulte HM, Loning T, Bamberger MC. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab.2000,85(10):3932-36.
56. Gazit E, Sherf M, Balbin E, Muratov A, Goldstein I, Loewenthal R. HLA-G expression is induced in Epstein-Barr virus-transformed B-cell lines by culture conditions. Hum Immunol.2007,68(6):463-68.
57. Rivero A, Lozano JM, Gonzalez R, Garcia-Jurado G, Camacho A, Torres-Cisneros J, et al. Nucleoside reverse transcriptase inhibitors are able and protease inhibitors unable to induce the tolerogenic molecule HLA-G 1 on monocytes from HIV-1 infected patients. Hum Immunol.2007,68(4):303-6.
58. Megret F, Prehaud C, Lafage M, Moreau P, Rouas-Freiss N, Carosella ED, et al. Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. Hum Immunol.2007,68(4): 294-302.
59. Lafon M, Prehaud C, Megret F, Lafage M, Mouillot G, Roa M, et al. Modulation of HLA-G expression in human neural cells after neurotropic viral infections. J Virol.2005,79(24):15226-37.
60. Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H. Detection of HLA-G5 secreting cells. Hum Immunol.2003,64(11):1017-24.
61. Blanco O, Tirado I, Munoz-Fernandez R, Abadia-Molina AC, Garcia-Pacheco JM, Pena J, et al. Human decidual stromal cells express HLA-G:Effects of cytokines and decidualization. Hum Reprod.2008,23(1):144-52.
62. Pizzato N, Garmy-Susini B, Le BP, Lenfant F. Down-regulation of HLA-G 1 cell surface expression in human cytomegalovirus infected cells. Am J Reprod Immunol.2003,50(4):328-33.
63. Yang Y, Geraghty DE, Hunt JS. Cytokine regulation of HLA-G expression in human trophoblast cell lines. J Reprod Immunol.1995,29(3):179-95.
64. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse:A molecular machine controlling T cell activation[J]. Science,1999,285(5425): 207-208.
65. Pacheco R, Martinez-Navio JM, Leune M, et al. CD26, adenosine deam inase, and adenosine receptors mediate costimulatory signals in the immunological synapse[J]. Proc Natl Acad Sci USA,2005,102(27):9583-9588.
66. Faroudi M, Utzny C, Salio M, et al. Lytic versus stimulatory synapsein cytotoxic T lymphocyte/target cell interaction:M an infestation of a dual activation threshold[J]. Proc Natl Acad Sci USA,2003,100(24):14145-14150.
67.Wulfing C, Davis MM. A recepter/cytoskeletal movement triggered by costimulating during T cell ctivating[J]. Science,1998,282(5397):2266-2269.
68. Davis DM, Chin I, Fassett M, et al. The human natural killer cell immune synapse [J]. Proc Natl Acad Sci USA,1999,96(26):15062-15067.
69.Vyas YM, Maniar H, Lyddane CE, et al. Ligand binding to inhibitory killer cell Ig-like recepters induce colocalization with Src homology domain 2-containing protein tyrosine I and interruption of ongoing activation signals[J]. J Immunol, 2004,173(3):1571-1578.
70. Tabiasco J, Vereelone A, Meggetto F, et al. Acquisition of viral receptor by NK cells through immunological synapse [J]. J Immunol,2003,170(12):5993-5998.
71.Poupot M, Fourine JJ. Spontaneous membrane transfer through homotypic synapse between lyphoma cells [J]. J Immunol.2003,171(5):2517-2523.
72.LeMaoult J, Caumartin J, Daouya M, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood, 2007,109(5):2040-8
73.Caumartin J, Favier B, Daouya M, et al. Trogocytosis-based generation of suppressive NK cells. Embo J,2007,26(5):1423-33.
1. Le Morvan C, Cogne M, Troutaud D, Charmes JP, Sauvage P, Drouet M. Modification of HLA expression on peripheral lymphocytes and monocytes during aging. Mech Ageing Dev.1998,105(3):209-20.
2. Suzuki H, Higuchi M, Hasegawa T, et al. Tissue array analysis of the aberrant expression of HLA class I molecules in human non small cell lung cancer. Gan To Kagaku Ryoho.2006,33(12):1713-6.
3. Kitamura H, Honma I, Torigoe T, et al. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol. 2007,177(4):1269-72.
4. Li J, Yang Y, Inoue H, et al. The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines:its regulation by interferon gamma and interleukin-10. Cancer Immunol Immunother,1996,43(4):213-219.
5. Chai JG, Vendetti S, Amofah E, Dyson J, Lechler R. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation. J Immunol.2000,165(6):3037-42.
6. Vlad QPiazza F,Colovai A. Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals. Hum Immunol.2003; 64(5):483-489.
7.Lucy Cassar, He Li, Fang-Xu Jiang, Jun-Ping Liu. TGF-P induces telomerase-dependent pancreatic tumor cell cycle arrest. Molecular and Cellular Endocrinology, In Press, Corrected Proof, Available online 6 February 2010.
8. Li Zeng, Colleen O'Connor, Jiayou Zhang. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine,2010,49(3):294-302.
9. Lorenzo Moretta, Roberto Biassoni, Cristina Bottino, et al. Human NK cells and their receptors. Microbes and Infection,2002,4(15):1539-1544.
10. Hsing-Chun Kuo, Wu-Hsien Kuo, Yean-Jang Lee. Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo. Cancer Letters,2006,234(2):199-208.
11. Nishimura H,Okazaki T,Tanaka Y.Autoimmune medilated cardiomyopathy in PD-1 receptor-deficient mice.Science,2001;291:319-323
12. Mitsuaki I,Hisanori K,Jun-ichi S. T cell costimulation in the development of cardiac allograft vasculopathy Arteriosclerosis,Thrombosis,and Vascular. Biology.2006;26:1447-1456
13. James L.Riley,Carl H.J. The CD28 family:a T-cell rheostat for therapeutic control of T-cell activation. Blood,2005;105:13-21
14. Oht su A, Yoshida S, Saijo N,et al. Disparities in gast ric cancer chemotherapy between the East and West [J]. J Clin Oncol,2006,24 (14):2188.
15. Cortesini R,LeMaoult J,Ciubotariu R,et al. CD8+CD28-T suppressor cells and theinduction of antigen-specific,antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev,2001,182:201-206.
16. Chang CC,Ciubotariu R,Manavalan JS,et al.Tolerization of dendritic cells by T(S)cells:the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol, 2002,3(3):237-243.
17. Steinman RM,Hawiger D,Nussenzweig MC.Tolerogenic dendritic cells.Annu RevImmunol,2003,21:685-711.
18. Coates PT,Colvin BL,Kaneko K,et al. Pharmacologic,biologic,and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity. Transplantation,2003,75:32-36.
19. Expression and function of immunoglobin-like transcripts on tolerogenic dendritic cells. Human immunology,2009,70:353-356.
20.Lutz MB,Schuler G. Immature,semi-mature and fully mature dendritic cells:which signals induce tolerance or immunity.Trends Immunol,2002,23:445-449.
21.Xiao BQWu XC,Yang JS,et al.Therapeutic potential of IFN-gmodified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol, 2004,16:13-22.
22. Adorini L,Giarratana N,Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells.Semi Immunol,2004,16:127-134.
23. Li G,Kim YJ,Broxmeyer HE. Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-10(high)-IL-12absent dendritic cells with tolerogenic potential.J Immunol,2005,174:4706-4717.
24.Taams LS, Akbar AN. Peripheral generation and function of CD4+CD25+ regulatory T cells.Curr Top Microbiol Immunol,2005,293:115-131.
25.Bohana-Kashtan O, Civin CI. Fas ligand as a tool for immunosuppression and generation of immune tolerance.Stem Cells,2004,22:908-924.
26.Mellor AL,Munn DH. IDO expression by dendritic cells:tolerance and tryptophan catabolism. Nat Rev Immunol,2004,4:762-774.
27. Siyuan Liang, Vladimir Ristich, Hisashi Arase,et al. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. PNAS,2008,17:8357-8362.
28. Suciu-Foca N, Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol.2007,248:59-67.
29. Rutella S,Bonanno G,Pierelli L,et al. Granulocyte colonystimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha.Eur J Immunol,2004,34:1291-1302.
30. Vlad G, Liu Z, Zhang QY, Cortesini R, Suciu-Foca N. Immunosuppressive activity of recombinant ILT3. Int Immunopharmacol.2006,6:1889-94.
31.Corinti S,Albanesi C,la Sala A,et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol,2001,166:4312-4318.
32.Vlad G, Cortesini R, Suciu-Foca N. CD8+T suppressor cells and the ILT3 master switch. Hum Immunol.2008;69:681-6.
33.Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad SciUSA.2003;100:8856-61.
34. Cai Zhang, Jian Zhang, Haiming Wei, Zhigang Tian. Imbalance of NKG2D and its inhibitory counterparts:How does tumor escape from innate immunity? International Immunopharmacology,2005,5(7-8):1099-1111.
35. Yuping Sun, Jie Liu, Ping Gao, et al. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest,2008, 134:783-788
36. Y. Fukushima, Y. Oshika, M. Nakamura, T. Tokunaga, H. Hatanaka and Y. Abe et al, Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mol Med,1998,2(3):349-351.
37. K. Leelawat, S Engprasert, U. Pongchai-rerk, et al. No expression of human leukocyte antigen G (HLA-G) in colorectal cancer cells, J Med Assoc Thai,2004, 87 (7):816-818.
38. Alessandro Poggi, Maria Raffaella Zocchi. Role of bone marrow stromal cells in the generation of human CD8+regulatory T cells. Human Immunology,2008, 69(11):755-759.
39. R.H. McIntire, J.S. Hunt. Antigen presenting cells and HLA-G-a review. Placenta,2005,26(Supplement 1):S104-S109.
40.Jonathan M. Wilson, P. Louise Coletta, Richard J. Cuthbert. Macrophage Migration Inhibitory Factor Promotes Intestinal Tumorigenesis. Gastroenterology, 2005,129(5):1485-1503.
1. S. Kovats, E.K. Main, C. Librach, M. Stubblebine, S.J. Fisher and R. DeMars, A class I antigen, HLA-G, expressed in human trophoblasts, Science.1990,248 (4952):.220-223.
2. S.A. Ellis, M.S. Palmer and A.J. McMichael, Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA Class I molecule, J Immunol.1990,144 (2):731-735.
3. Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A, Wiendl H. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation.Blood.2007,110(2):568-77.
4. N. Rouas-Freiss, R.M. Goncalves, C. Menier, J. Dausset and E.D.D. Carosella, Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci.1997,94 (21):11520-11525
5. E. D. Carosella, B. Favier, N. Rouas-Freiss, P. Moreau, and J. LeMaoult.Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood, 2008; 111(10):4862-4870.
6. Abderrahim Naji, Antoine Durrbach, Edgardo D. Carosella, Nathalie Rouas-Freiss. Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways. Human Immunology,2007,68:233-239
7. Christian A. Gleissner, Thomas J. Dengler. Induction of ILT expression on nonprofessional antigen presenting cells:Clinical applications. Human Immunology,2009,70:357-359
8. Y. Sun, J. Liu, P. Gao, Y. Wang, and C. Liu. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest, October 1,2008; 134(4):783-788.
9. Zhang Yi, Liu Yang, Lu Nan, et al. Rapid detection of HLA genes expression in Peripheral Blood Mononuclear Cell of Gastric Cancer Patients by reverse transcriptase polymerase chain reaction.978-1-4244-2902-8/09(?)2009 IEEE
10.Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H. Quantitative real-time RT-PCR data analysis:current concepts and the novel "gene expression's CT difference" formula. J Mol Med.2006,84(11):901-10.
11. Donald CE, Qureshi F, Burns MJ, Holden MJ, Jr Blasic JR, Woolford AJ. An inter-platform repeatability study investigating real-time amplification of plasmid DNA. BMC Biotechnol.2005,5:15.
12. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class Ⅰ gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci USA.1987,84(24):9145-49.
13. Tomasoni S, Remuzzi G, Benigni A. Allograft rejection:acute and chronic studies. Contrib Nephrol.2008,159:122-34.
14. Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol.1994, 153(12):5516-24.
15. P. Le Bouteiller. HLA-G et immunite placentaire localeHLA-G and local placental immunity. Gynecologie Obstetrique & Fertilite,2003,31:782-785
16. Astrid M. Kolte, Rudi Steffensen, Henriette S, et al. Nielsen. Study of the structure and impact of human leukocyte antigen (HLA)-G-A, HLA-G-B, and HLA-G-DRB1 haplotypes in families with recurrent miscarriage. Human Immunology, In Press, Corrected Proof, Available online 19 February 2010
17. Lemaoult J, Le DM, Rouas-Freiss N, Moreau P, Menier C, Mccluskey J, et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens.2003,62(4):273-84.
18. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G:from biology to clinical benefits. Trends Immunol.2008,29(3):125-32.
19. M. Urosevic, J. Willers, B. Mueller, W. Kempf, G. Burg and R. Dummer, HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas, Blood.2002,99 (2):609-617
20. P. Paul, F.A. Cabestre, F.A. Le Gal, Ⅰ. Khalil-Daher, C. Le Danff and M. Schmid et al., Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies, Cancer Res.1999,59 (8):1954-1960.
21. S. Aractingi, J. Kanitakis, S. Euvrard, C. Le Danff and E.D Carosella, Selective expression of HLA-G in malignant and premalignant skin specimens in kidney transplant recipients, Int J Cancer.2003,106 (2):232-235。
22. D.E. Hansel, A. Rahman, R.E. Wilentz, M. Shih Ie, M.T. McMaster and C.J. Yeo et al., HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract, Int J Gastrointest Cancer.2005,35 (1):15-23.
23. Y. Fukushima, Y. Oshika, M. Nakamura, T. Tokunaga, H. Hatanaka and Y. Abe et al., Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells, Int J Mol Med.1998,2 (3):349-351.
24. S.R. Ye, H. Yang, K. Li, D.D. Dong, X.M. Lin and S.M. Yie, Human leukocyte antigen G expression:as a significant prognostic indicator for patients with colorectal cancer, Mod Pathol.2007,20 (3):375-383.
25. M. Urosevic, M.O. Kurrer, J. Kamarashev, B. Mueller, W. Weder and G. Burg et al., Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class Ⅰ loss and interleukin-10 production, Am J Pathol.2001,159 (3):817-824.
26.B. Davidson, B. Risberg, A. Berner, C.W. Bedrossian and R. Reich, The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma, Semin Diagn Pathol.2006,23 (1):35-43.
27.B. Davidson, B. Risberg, A. Berner, C.W. Bedrossian and R. Reich, The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma, Semin Diagn Pathol.2006,23 (1):35-43.
28. E.C. Ibrahim, N. Guerra, M.J. Lacombe, E. Angevin, S. Chouaib and E.D Carosella et al., Tumor-specific up-regulation of the nonclassical class Ⅰ HLA-G antigen expression in renal carcinoma, Cancer Res.2001,61 (18):6838-6845.
29. J. Bukur, V. Rebmann, H. Grosse-Wilde, H. Luboldt, H. Ruebben and I. Drexler et al., Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma, Cancer Res.2003,63 (14):4107-4111.
30. J. Bukur, B. Malenica, C. Huber and B. Seliger, Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response, Hum Immunol.2003,64 (11): 1081-1092.
31. C. Ibrahim el, Y. Allory, F. Commo, et al. Altered pattern of major histocompatibility complex expression in renal carcinoma. Am J Pathol.2003,162 (2):501-508.
32. B.F. Barrier, B.S. Kendall, K.L. Sharpe-Timms and E.R. Kost, Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma, Gynecol Oncol.2006,103 (1):25-30.
33. M. Ponte, C. Cantoni, R. Biassoni, et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy:decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G 1-specific receptor. Proc Natl Acad Sci USA.1999,96 (10):5674-5679.
34. D.R. Bainbridge, S.A. Ellis and I.L. Sargent, HLA-G suppresses proliferation of CD4(+) T-lymphocytes, J Reprod Immunol.2000,48 (1):17-26.
35. S. Fournel, M. Aguerre-Girr, X. Huc, et al., Cutting edge:soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol.2000,164 (12):6100-6104.
36. S. Rajagopalan and E.O. Long, A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med.1999, 189(7):1093-1100.
37. Contini P, Ghio M, Poggi A, et al. Soluble HLA-A,-B,-C and-G molecules induce apoptosis in T and NK CD8+cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol.2003,33(1):125-34.
38. Puppo F, Contini P, Ghio M, Indiveri F. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+cells by Fas/Fas-ligand interaction. Scientific World Journal.2002,2:421-23.
39. Fang CY, Wu XW, Liang ZH, et al. Immune tolerance inducing effects of soluble human leucocyte antigen Gl on natural killer cells and T cells. Zhonghua Yi Xue Za Zhi.2003,83(7):584-87.
40. Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol.2006,176(3):1331-39.
41. Lemaoult J, Zafaranloo K, Le DC, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. Faseb J. 2005,19(6):662-64.
42. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol.2000,48(1):17-26.
43. N. Lila, N. Rouas-Freiss, J. Dausset, A. Carpentier and E.D Carosella, Soluble HLA-G protein secreted by allo-specific CD4+T cells suppresses the allo-proliferative response:a CD4+T cell regulatory mechanism, Proc Natl Acad Sci USA.2001,98 (21):12150-12155.
44. Maejima M, Fujii T, Kozuma S, Okai T, Shibata Y, Taketani Y. Presence of HLA-G-expressing cells modulates the ability of peripheral blood mononuclear cells to release cytokines. Am J Reprod Immunol.1997,38(2):79-82.
45. Hamai Y, Fujii T, Yamashita T, et al. Peripheral blood mononuclear cells from women with recurrent abortion exhibit an aberrant reaction to release cytokines upon the direct contact of human leukocyte antigen-G-expressing cells. Am J Reprod Immunol.1998,40(6):408-13.
46. Hamai Y, Fujii T, Yamashita T, Miki A, et al. The expression of human leukocyte antigen-G on trophoblasts abolishes the growth-suppressing effect of interleukin-2 towards them. Am J Reprod Immunol.1999,41(2):153-58.
47. Kanai T, Fujii T, Unno N, et al. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood.2001,45(2):94-99.
48. Rieger L, Hofmeister V, Probe C, Dietl J, et al. Thl-and Th2-like cytokine production by first trimester decidual large granular lymphocytes is influenced by HLA-G and HLA-E. Mol Hum Reprod.2002,8(3):255-61.
49. Van Der Meer A, Lukassen HG, Van Cranenbroek B, Weiss EH, Braat DD, Van Lierop MJ, et al. Soluble HLA-G promotes Thl-type cytokine production by cytokine-activated uterine and peripheral natural killer cells. Mol Hum Reprod. 2007,13(2):123-33.
50. Joly E, Hudrisier D. What is trogocytosis and what is its purpose?. Nat Immunol. 2003,4(9):815.
51. Lemaoult J, Caumartin J, Daouya M, Favier B, Le RS, Gonzalez A, et al. Immune regulation by pretenders:cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood.2007,109(5):2040-48.
52. Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A, et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood.2007,110(2):568-77.
53. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, et al. Trogocytosis-based generation of suppressive NK cells. Embo J.2007,26(5): 1423-33.
54. Selmani Z, Naji A, Zidi I, Favier B, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+regulatory T cells. Stem Cells.2008,26(1):212-22.
55. Le MA, Noel G, Birebent B, Grosset JM, Vu N, De Guibert S, et al. Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation:a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol.2008,152(1):50-56.
56.张义,邹雄,杨晓静,李晓丽,赵胜梅,高艳景.淋巴细胞HLA-B表达与胃癌分化转移的关系.中华肿瘤杂志,2007,29：49-52
57. Lu N, Wan F, Yang X, Wang C, Yi Z, et al. Qa-2 mRNA in peripheral blood mononuclear cells, a Potential Marker for Acute Allograft Rejection. Med Sci Monit,2009,15(4):BR99-105.
58. P. Paul, N. Rouas-Freiss, I. Khalil-Daher, P. Moreau, B. Riteau and F.A. Le Gal et al., HLA-G expression in melanoma:a way for tumor cells to escape from immunosurveillance, Proc Natl Acad Sci USA.1998,95 (8):4510-4515.
59. H.M. Hurks, M.M. Valter, L. Wilson, I. Hilgert, P.J. van den Elsen and M.J. Jager, Uveal melanoma:no expression of HLA-G, Invest Ophthalmol Vis Sci.2001,42 (13):3081-3084.
60.Fukushima Y, Oshika Y, Nakamura M, et al. Increase expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mol Med, 1998,2(3):349-51.
61. B.F. Barrier, B.S. Kendall, K.L. Sharpe-Timms and E.R. Kost, Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma, Gynecol Oncol.2006,103 (1):25-30.
62. Erinn Downs-Kelly, Andrew E. Schade and Donna E. Hansel. The role of HLA-G in gastrointestinal inflammatory disease and malignancy. Seminars in Cancer Biology.2007,17 (6):451-458
63. Myriam Onno, Gaelle Le Friec, Celine Pangault, et al. Modulation of HLA-G antigens expression in myelomonocytic cells. Human Immunology,2000,61(11):1086-1094.
64. Y. Fukushima, Y. Oshika, M. Nakamura, T. Tokunaga, et al., Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells, Int J Mol Med.1998,2 (3):349-351.
65. K. Leelawat, S. Engprasert, U. Pongchai-rerk, S. Tuchinda, C. Suthipintawong and V. Leardkamolkarn, No expression of human leukocyte antigen G (HLA-G) in colorectal cancer cells, J Med Assoc Thai.2004,87 (7):816-818.
66. D.E. Hansel, A. Rahman, R.E. Wilentz, et al., HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract, Int J Gastrointest Cancer.2005,35(1):15-23.
67. J. Caumartin, B. Favier, M. Daouya, C. Guillard, P. Moreau and E.D Carosella et al., Trogocytosis-based generation of suppressive NK cells, Embo J.2007,26 (5):1423-1433.
1. Hiromichi Kawaida, Koji Kono, Akihiro Takahashi. et al. Distribution of CD4(+) CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. Journal of Surgical Research,2005,124,:151-157
2. Stefanie Gross, Peter Walden. Immunosuppressive mechanisms in human tumors:Why we still cannot cure cancer. Immunology Letters,2008,116:7-14.
3. Katsuiku Hirokawa, Masanori Utsuyama, Toshiaki Ishikawa. et al. Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mechanisms of Ageing and Development.2009,130:86-91
4. John K. Petty, Ken He, Christopher L.et al. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). The American Journal of Surgery,2002,183:512-518
5. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science.2000,6:290 (5489):84-9.
6. George Vlad, Raffaello Cortesini, Nicole Suciu-Foca. CD8+ T suppressor cells and the ILT3 master switch. Human Immunology,2008,69:681-686.
7. Jinyi Zhang, Ally-Khan Somani, Katherine A. Siminovitch. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Seminars in Immunology,2000,12(4):361-378.
8. Yuping Sun, Jie Liu, Ping Gao, et al. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest, 2008,134:783-788.
9.Boris Fedoric, Ravi Krishnan. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunology Letters, 2008,120:49-56.
10. Favier B, Lemaoult J, Lesport E. et al. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J.2010;24(3):689-99.
11. Christian A. Gleissner, Thomas J. Dengler. Induction of ILT expression on nonprofessional antigen presenting cells:Clinical applications. Human Immunology,2009 70(5):357-359.
12. Homfeister,V and EH Weiss. HLA-G modulates immune responses by diverse receptor interactions.Semin Cancer Biol,2003,13:317.
13.A. Monsiva'is-Urenda, P. Ni-no-Moreno, C. Abud-Mendoza, et al. Analysis of expression and function of the inhibitory receptor ILT2 in peripheral blood mononuclear cells frompatients with systemic lupus erythematosus (SLE). Journal of Autoimmunity,2007,29:97-105.
14.Xin-Sheng Ju, Christine Hacker, Barbara Scherer, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene,2004,31:159-164.
15.Shiroishi M, K Tsumoto, K Amno, et al. Human inhibitory receptors Ig-like transcriptor 2(ILT2) and ILT4 compete with CD8 for MHC-class I binding and bind preferentially to HLA-G. Natl Acad Sci USA,2003,100:8856.
16. John S. Manavalan, Paola C. Rossi, George Vlad, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transplant Immunology,2003,11 (3-4):245-258.
17.Juan Wu and Anatolij Horuzsko. Expression and function of immunoglobin-like transcripts on tolerogenic dendritic cells. Human Immunology.2009,70: 353-356.
18. Urban Svajger, Alenka Vidmar, Matjaz Jeras. Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ILT3 and ILT4. International Immunopharmacology,2008,8(7):997-1005
19. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by humandendritic cells and down-regulated following activation. Gene, 2004:331:159-64.
20. Suciu-Foca N, Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol.,2007:248:59-67.
21. Idan Tamir, Joseph M Dal Porto, John C Cambier. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2:regulators of B cell signal transduction. Current Opinion in Immunology,2000,12(3):307-315.
22. Leonie S. Taams, Jocea M.R. van Amelsfort, Machteld M. Tiemessen. et al. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Human Immunology,2005,66:222-230.
23. Vlad G, Cortesini R, Suciu-Foca N. CD8+T suppressor cells and the ILT3master switch. Hum Immunol,2008:69:681-6.
24. Ariel Munitz. Inhibitory receptors on myeloid cells:New targets for therapy? Pharmacology & Therapeutics, January 2010,125(1):128-137.
25. Judith Leitner, Katharina Grabmeier-Pfistershammer, Peter Steinberger. Receptors and ligands implicated in human T cell costimulatory processes. Immunology Letters,2010,128(2):89-97.
1 Waldhauer Ⅰ, Steinle A:NK cells and cancer immunosurveillance. Oncogene 2008; 6:5932-5943.
2 Seliger B:Molecular mechanisms of MHC class Ⅰ abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008; 57: 1719-1726.
3 Holling TM, Schooten E, van Den Elsen PJ:Function and regulation of MHC class Ⅱ molecules in T-lymphocytes:of mice and men. Hum Immunol 2004; 65:282-290.
4 Groothuis T, Neefjes J:The ins and outs of intracellular peptides and antigen presentation by MHC class Ⅰ molecules. Curr Top Microbiol Immunol 2005; 300:127-148.
5 Williams A, Peh CA, Elliott T:The cell biology of MHC class I antigen presentation. Tissue Antigens 2002; 59:3-17.
6 Chiba M, Ishii N, Ishioka T, et al:Topographic study of Helicobacter pylori and HLA-DR antigen expression on gastric epithelium. J Gastroenterol 1995; 30:149-155.
7 Maeurer MJ, Gollin SM, Martin D, et al:Tumor escape from immune recognition:lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996; 98:1633-1641.
8 Plaksin D, Gelber C, Feldman M, et al:Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. Proc Natl Acad Sci USA 1988; 85:4463-4467.
9 Schefe JH, Lehmann KE, Buschmann IR, et al:Quantitative real-time RT-PCR data analysis:current concepts and the novel "gene expression's CT difference" formula. J Mol Med 2006; 84:901-910.
10 Breton F. Barrier, Brian S, et al:Characterization of human leukocyte antigen-G(HLA-G) expression in endometrial adenocarcinoma. ynecologic Oncology 2006; 103:25-30.
11 Nathalie Rouas-Freiss, Philippe Moreau, Catherine Menier, et al:HLA-G in cancer:a way to turn off the immune system. Seminars in Cancer Biology 2003; 13:325-336.
12 Collins RW:Human MHC class I chain related (MIC) genes:their biological function and relevance to disease and transplantation. Eur J Immunogenet 2004; 31:105-114.
13 Wedekind C, Walker M, Little TJ:The separate and combined effects of MHC genotype, parasite clone, and host gender on the course of malaria in mice. BMC Genet 2006; 7:55.
14 Wu JD, Atteridge CL, Wang X, et al: Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 2009; 15:632-640.
15 Le Morvan C, Cogne M, Drouet M:HLA-A and HLA-B transcription decrease with ageing in peripheral blood lymphocytes. Clin Exp Immunol 2001:125:245-250.
16 Abendroth A, Arvin A:Varicella-zoster virus immune evasion. Immunol Rev 1999; 168:143-156.
17 Morrow G, Slobedman B, Cunningham AL, et al: Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol 2003; 77:4950-4959.
18 Lanier.L.L. NK cell receptors. Annu.Rev.Immuol 1998; 16:359-393.
19 Moretta.L., Biassoni.R., Bottino.C., et al: NK-cell receptors. Immunol.Today 2000; 21:420-422.
20 Trowsdale.J. Genetic and functional relationships between MHC and NK receptor genes. Immunity 2001; 15:363-374.
21 Yokoyama.W.M. & Plougastel, B.F. Immune functions encoded by the natural killer gene complex. Nature Rev. Immunol.2003; 3:304-316.
22 Kim S, Poursine-Laurent J, Truscott SM, et al: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005:436:709-713.
23 Zhang Y, Zou X, Yang XJ, et al: Relationship between the expression of human leukocyte antigen-B in peripheral blood leukocytes and the differentiation and metastasis of gastric carcinoma. Zhonghua Zhong Liu Za Zhi 2007; 29:49-52 [in Chinese].
24 Mouillot G, Marcou C, Zidi I, et al: Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007; 68:277-285.
25 Zeng MH, Fang CY, Wang SS, et al A study of HLA-G1 protecting porcine endothelial cells against human natural killer cell-mediated cytotoxicity. Transplant Proc 2006; 38:3312-3314.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics,2002[J]. CA ancer J Clin,2005,55(2):742108.
3. Oht su A, Yoshida S, Saijo N,et al. Disparities in gast ric cancer chemotherapy between the East and West [J]. J Clin Oncol,2006,24 (14):2188.
4. Hiromichi Kawaida, Koji Kono, Akihiro Takahashi. et al. Distribution of CD4(+) CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. Journal of Surgical Research,2005,124,:151-157
5. Toni Aebischer, Bernadette Lucas, Jan Koesling. et al. How CD4+T cells may eliminate extracellular gastric Helicobacter? Journal of Biotechnology,2000,83: 77-84
6. Katsuiku Hirokawa, Masanori Utsuyama, Toshiaki Ishikawa. et al. Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mechanisms of Ageing and Development.2009,130:86-91
7. Calin Stoicov, Reza Saffari, Xun Cai.et al. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma:bacterial and host factors responsible for altered growth signaling. Gene,341,27:1-17
8. C. A. Schmitt, W. Schwaeble, B. M. Wittig. et al. Expression and regulation by interferon-y of the membrane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 in gastrointestinal tumours. European Journal of Cancer,1999,35: 117-124
9. Hinrich Abken, Andreas Hombach, Claudia Heuser, et al. Tuning tumor-specific T-cell activation:a matter of costimulation? Trends in Immunology,2002,23: 240-245.
10. Ninke Leffers, Annechien J.A. Lambeck, et al. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation. Gynecologic Oncology,2008,10:365-373.
11. Nick Kassouf, Martin H. Thornhill. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-a, to induce apoptosis in Jurkat T cells:Possible mechanisms for immune escape by head and neck cancers. Oral Oncology,2008, 44:672-682.
12. Eleftherios P. Diamandis. Clinical applications of tumor suppressor genes and oncogenes in cancer. Clinica Chimica Acta,1997,257:157-180
13. Tomoko Amachika, Daisuke Kobayashi, Ryosuke Moriai, et al. Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer,2007,56:337-340
14. Martin Loos, Nathalia A. Giese, Jorg Kleeff, et al. Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. Cancer Letters,2008,268:98-109
15. John K. Petty, Ken He, Christopher L.et al. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). The American Journal of Surgery,2002,183:512-518
16. K.H. Haraldsdottir, K. Ivarsson, S. Gotberg, et al. Interstitial laser thermotherapy (ILT) of breast cancer. European Journal of Surgical Oncology,2008,34:739-745
17. Stefanie Gross, Peter Walden. Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer. Immunology Letters,2008,116:7-14
18. George Vlad, Raffaello Cortesini, Nicole Suciu-Foca. CD8+T suppressor cells and the ILT3 master switch. Human Immunology,2008,69:681-686
19. Leonie S. Taams, Jocea M.R. van Amelsfort, Machteld M. Tiemessen. et al. Modulation of monocyte/macrophage function by human CD4+CD25+regulatory T cells. Human Immunology,2005,66:222-230
20. Lefebvre S, Antoine M, Uzan S,et al. Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer. J Pathol.2002,196(3):266-74.
21. Favier B, Lemaoult J, Lesport E. et al. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J.2010;24(3):689-99.
22. Yuping Sun, Jie Liu, Ping Gao, et al. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest,2008,134: 783-788
23.Van der Slik AR,Koeleman BP,Verduijn W.KIRS intype 1 diabetes:disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects.Diabetes,2003,52(10):2639-2645.
24.Nishimura H,Minato N,Nakano T.Immunological studies on PD-1-deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int.Immunol, 1998,10:1563-1568
25.Nishimura H,Nose M,Hiai H.Development of lupus-like autoimmune diseases by disruption of the PD-1gene encoding an ITIM motif-carrying immuno-receptor. Immunity,1999,11:141-145
26. Liang Shan, Qifeng Yang, Misa Nakamura, et al. Active Allele Loss of the Androgen Receptor Gene Contributes to Loss of Androgen Receptor Expression in Female Breast Cancers. Biochemical and Biophysical Research Communications, 2000,275:488-492
27. M. Maynadier, J.M. Ramirez, A.M. Cathiard, N, et al. Inhibitory effects of unliganded estrogen receptor alpha on breast cancer cell growth and invasion. European Journal of Cancer Supplements,2008,6:22
28. K Detjen, M C Fenrich, C D Logsdon. Transfected cholecystokinin receptors mediate growth inhibitory effects on human pancreatic cancer cell lines. Gastroenterology,1997,112:952-959
29. Alison Crawford, E John Wherry. The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. Current Opinion in Immunology,2009,21:179-186
30. Boris Fedoric, Ravi Krishnan. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunology Letters,2008, 120:49-56
31. Abderrahim Naji, Antoine Durrbach, Edgardo D. Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways. Human Immunology,2007,68(4):233-239.
32. Christian A. Gleissner, Thomas J. Dengler. Induction of ILT expression on nonprofessional antigen presenting cells:Clinical applications. Human Immunology,2009,70(5):357-359.
33. C Gleissner, A Zastrow, R Klingenberg, N Xia, T.J Dengler. IL-10 induces suppressor of cytokine secretion-3 (SOCS-3) and ILT-3 in human endothelial cells and inhibits T cell costimulation. The Journal of Heart and Lung Transplantation, Volume 22, Issue 1, Supplement 1, January 2003, Page S81
34. Abderrahim Naji, Antoine Durrbach, Edgardo D. Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways. Human Immunology,2007,68(4): 233-239.
35. A. Monsivais-Urenda, P. Nino-Moreno, C. Abud-Mendoza. Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). Journal of Autoimmunity,2007,29:97-105
36. Idan Tamir, Joseph M Dal Porto, John C Cambier. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2:regulators of B cell signal transduction. Current Opinion in Immunology,2000,12(3):307-315.
37. Chengyu Wu, Mingzhong Sun, Lijun Liu, G. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene,2003,306(13):1-12.
38. Jinyi Zhang, Ally-Khan Somani, Katherine A. Siminovitch. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Seminars in Immunology,2000,12(4):361-378
39. Toshio Inoue, Yoshihiro Suzuki, Kazuya Mizuno, et al. SHP-1 exhibits a pro-apoptotic function in antigen-stimulated mast cells:Positive regulation of mitochondrial death pathways and negative regulation of survival signaling pathways. Molecular Immunology,2009,47:222-232
40. Samaridis J, Colonna M_1997.Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells:structural evidence for new stimulatory and inhibitory pathways. Eur J Immunol 27:660-665
41. Cella M, Dohring C, Samaridis J, Dessing M, Brockhaus M, Lanzavecchia A, Colonna M_1997. A novel inhibitory receptor ILT3. expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185:1743-1751
42. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity,1997,7:273-282.
43. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, L'opez-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med.1997,186:1809-1818
44. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol.1998,160:3096-3100
45. Fanger NA, Cosman D, Peterson L, Braddy SC, Maliszewski CR, Borges L. The MHC class I binding proteins LIR-1 and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur J Immunol.1998,28:3423-3434
46. Nakajima H, Samaridis J, Angman L, Colonna M. Human myeloid cells express an activating ILT receptor ILTl.that associates with Fc receptor gamma-chain. J Immunol.1999,162:5-8
47. Xin-Sheng Ju, Christine Hacker, Barbara Scherer, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene,2004,31:159-164
48. Yasuo Shirakihara, Linda Rasubala, P. Anton van der Merwe, et al. Entropically Driven MHC Class I Recognition by Human Inhibitory Receptor Leukocyte Ig-like Receptor B1 (LILRB1/ILT2/CD85j). Journal of Molecular Biology,2006, 55:237-248
49. Tara L. Chapman, Astrid P. Heikema, et al. Crystal Structure and Ligand Binding Properties of the D1D2 Region of the Inhibitory Receptor LIR-1 (ILT2). Immunity, 2000,13:727-736
50. Paula Bonorino, Muhammad Ramzan, Xavier Camous, et al. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C. Journal of Hepatology,2009,51:458-467
51. Miguel Lopez-Botet, Manuel Llano, Francisco Navarro, et al. NK cell recognition of non-classical HLA class I molecules. Seminars in Immunology,2000, 12:109-119
52. L.M.A. Balderas-Pena, S.D. Toro-Arreola, T. Garcia-Iglesias, et al. Placental expression of HLA-G, and its correlation with ILT2 expression on surface of CD4+ T lymphocytes and NK cells in preeclamptic women. Journal of Reproductive Immunology,2006,71:170-171
53. Claudia S. Wagner, Alexander Rolle, et al. Structural Elements Underlying the High Binding Affinity of Human Cytomegalovirus UL18 to Leukocyte Immunoglobulin-like Receptor-1. Journal of Molecular Biology,2007, 373(3):695-705
54. Yong Chen, Feng Gao, Fuliang Chu, et al. Crystal Structure of Myeloid Cell Activating Receptor Leukocyte Ig-like Receptor A2 (LILRA2/ILT1/LIR-7) Domain Swapped Dimer:Molecular Basis for Its Non-binding to MHC Complexes. Journal of Molecular Biology,2009,386:841-853
55. George Vlad, Zhuoru Liu, Qing-Yin Zhang, et al. Immunosuppressive activity of recombinant ILT3. International Immunopharmacology,2006,4:1889-1894
56. Nicole Suciu-Foca, Raffaello Cortesini. Central role of ILT3 in the T suppressor cell cascade. Cellular Immunology,2007,248:59-67
57. John S. Manavalan, Paola C. Rossi, George Vlad, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transplant Immunology, 2003,11:245-258
58. John S. Manavalan, George Vlad, Seunghee Kim-Shulze, et al. Generation of tolerogenic antigen presenting cells:crucial role of inhibitory receptors ILT3 and ILT4. Human Immunology,2003,64:S21
59. Adriana I. Colovai, Lawrence Tsao, Hana Lin, et al.21-OR:Expression of inhibitory receptors ILT3 and ILT4 on neoplastic B cells from patients with high-risk chronic lymphocytic leukemia:Implications for allogeneic stem cell transplantation. Human Immunology,2007,68:S111
60. ColonnaM, H.Nakajima, and M. Cella. Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells. J Leukoc Biol,1999; 66:718.
61.Colonna M, J Smaaridis, M Cella, etal. Human myelomonocytic cells express an Inhibitory receptor for classic and nonclassic MHCI classic molecues. J Immunol, 1998;160:3096.
62.ColonnaM, H.Nakajima, and M.Cella.A family of inhibitory and activating Ig-like receptors that modulate founction of lymphoid and myeloid cells.Semin Immunol, 2002;12:121.
63.Raveteh JV, and LL.Lnaier. Immune inhibitory receptors. Science.2000,290: 84.
64. Allan.DS, M Colonna, LL. Lanier, etal. Tetrameric complexes of human Histocompatibility leukoeyt antigen (HLA)-G bind to peripheral blood myelomonocytic cells J ExP Med.1999;189:1149.
65.Allan DS, EJ Lepin, VM Braud, et al. Tetrameric comples of HLA-E, HLA-F and HLA-G..J Immunol-Methods.2002,268:43
66.Allen RL, T Raine, A Haude, et al. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol,2001,167:5543
67.Lepin EJ, JM Bastin, DS Allan, et al. Functional characterization of HLA-F and binding of HLA-F terramers to ILT2 and ILT4 receptors. Eur J immunol.2000, 30:3552
68. Young NT, FC anvaez,; M Uhrberg, et al.Conserved organization of the ITL/LIR Gene family within the Polymoprhic human leukoeyte receptor complex. Immunogeneties,2001,53:270.
69. Homfeister,V and EH Weiss. HLA-G modulates immune responses by diverse receptor interactions.Semin Cancer Biol,2003,13:317.
70.Shiroishi M, K Tsumoto, K Amno, et al. Human inhibitory receptors Ig-like transcriptor 2(ILT2) and ILT4 compete with CD8 for MHC-class I binding and bind preferentially to HLA-G. Natl Acad Sci USA,2003,100:8856
71. Marco Colonna, Hideo Nakajima, Marina Cella. A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Seminars in Immunology.2000,12:121-127.
72. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol.2000,48(1):17-26.
73. Claudia S. Wagner, Alexander Rolle, David Cosman, et al. Structural Elements Underlying the High Binding Affinity of Human Cytomegalovirus UL18 to Leukocyte Immunoglobulin-like Receptor-1. Journal of Molecular Biology,2007, 373(3):695-705
74. Bo Dupont, Katharine C Hsu. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Current Opinion in Immunology,2004,16(5):634-643.
75. Idan Tamir, Joseph M Dal Porto, John C Cambier. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2:regulators of B cell signal transduction. Current Opinion in Immunology,2000,12(3):307-315.
76. Sabek O, Dorak MT, Kotb M, Gaber AO, Gaber L. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation.2002,74(5):701-7.
77. Roge R, Thorsen J, Toning C, Ozbay A, Moller BK, Carstens J. Commonly used reference genes are actively regulated in in vitro stimulated lymphocytes. Scand J Immunol.2007,65(2):202-9.
1. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance inpregnancy. FASEB J,2005,19:681-93.
2. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. nnuRev Immunol.2003,21:685-711.
3.Moseman EA, Liang X, Dawson AJ, etal. Human plasmacytoid dendritic cells activated by CpG oligo deoxynucleotidesinduce the generation of CD4+CD25+
regulatory T cells. J Immunol,2004; 173:4433-42.
4. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, et al.Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by humandendritic cells and down-regulated following activation. Gene,2004; 331: 159-64.
5. Suciu-Foca N, Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 2007;248:59-67.
6. A. Monsiva'is-Urenda, P. Ni-no-Moreno, C. Abud-Mendoza, et al. Analysis of expression and function of the inhibitory receptor ILT2 in peripheral blood mononuclear cells frompatients with systemic lupus erythematosus (SLE). Journal of Autoimmunity,2007,29:97-105.
7. M.J. Benito, M. Lopez-Hoyos, G. Fernandez-Fresnedo, Changes in the Expression of the Immunoglobulin-like Transcript 3(ILT3) and ILT4 Receptors in Renal Allograft Recipients:Effect of Donor and Recipient Aging. Transplantation Proceedings,2008,40:2894-2896.
8. Valeska Hofmeister, Elisabeth H. Weiss. HLA-G modulates immune responses by diverse receptor interactions. Seminars in Cancer Biology,2003,13:317-323.
9. Xin-Sheng Ju, Christine Hacker, Barbara Scherer, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene,2004,31:159-164.
10. ColonnaM, H.Nakajima, and M.Cella.A family of inhibitory and activating Ig-like receptors that modulate founction of lymphoid and myeloid cells.Semin Immunol, 2002;12:121.
11. Allan.DS, M Colonna, LL. Lanier, etal. Tetrameric complexes of human Histocompatibility leukoeyt antigen(HLA)-G bind to peripheral blood myelomonocytic cells .J ExP Med,1999;189:1149.
12. Yuping Sun, Jie Liu, Ping Gao, et al. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest,2008,134:783-788.
13.Neel Sengupta, Tammie S. MacFie, Thomas T. MacDonald, et al. Cancer immunoediting and "spontaneous" tumor regression. Pathology-Research and Practice,2010,206(1):1-8.
14. Sophie Lefebvre, Francisco Adrian, Philippe Moreau, et al. Modulation of HLA-G expression in human thymic and amniotic epithelial cells. Human Immunology, Ⅴ 2000,61(11):1095-1101.
15. Joel LeMaoult, Nathalie Rouas-Freiss, Edgardo D. Carosella. Immuno-tolerogenic functions of HLA-G:Relevance in transplantation and oncology. Autoimmunity Reviews,2005,4(8):503-509.
16.Jes Dietrich, Hideo Nanajima, Marco Colonna. Human inhibitory and activating Ig-like receptors which modulate the function of myeloid cells. Microbe and infection.2000,2:323-329.
17. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science.2000,6:290 (5489):84-9.
18. Samaridis J, Colonna M. Cloning of novel immunoglobulin super family receptors expressed on human myeloid and lymphoid cells:structural evidence for new stimulator yand inhibitory pathways. Eur J Immunol,1997,27:660-665.
19. Wende H, Colonna M, Ziegler A, Volz A. Organization of the leukocyte receptor cluster LRC on human chromosome19q13.4. Mamm Genome,1999,10:154-160
20. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, et al. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class Ⅰ molecules. J Immunol 1998;160:3096-3100.
21. Vlad G, Cortesini R, Suciu-Foca N. CD8+T suppressor cells and the ILT3master switch. Hum Immunol 2008;69:681-6.
22. Cortesini R, Suciu-Foca N. ILT3+ ILT4+ tolerogenic endothelial cells in transplantation. Transplantation,2006;82:S30-2.
23. Colonna M, Nakajima H, Navarro F, Lopez-Botet M. A novel family of Ig-likereceptors for HLA class I molecules that modulate function of lymphoid andmyeloid cells. J Leukoc Biol 1999;66:375-81.
24. C.-C. Chang, N. Oberfield, P. Satwani, et al. Differential gene expression profiles of the CD4+CD25+ T suppressor (Ts) cell population in human cord blood and adult peripheral blood vs murine spleen cells. Biology of Blood and Marrow Transplantation,2004,10(1):46.
25. John S. Manavalan, Paola C. Rossi, George Vlad, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transplant Immunology, 2003,11(3-4):245-258.
26.Juan Wu and Anatolij Horuzsko. Expression and function of immunoglobin-like transcripts on tolerogenic dendritic cells. Human Immunology.2009,70:353-356
27. Manavalan JS, Rossi PC, Vlad G, Piazza F, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol,2003, 11:245-58.
28. Vlad G, Cortesini R, Suciu-Foca N. CD8+ T suppressor cells and the ILT3master switch. Hum Immunol,2008;69:681-6.
29. Chang CC, Ciubotariu R, Manavalan JS, Yuan J, Colovai AI, et al. Tolerization of dendritic cells by T(S) cells:The crucial role of inhibitoryreceptors ILT3 and ILT4. Nat Immunol.2002;3:237-43.
30. Pavlina Braunfuchsova, Ji Salat, Jan Kopecky. CD8+ T lymphocytes protect SCID mice against Encephalitozoon cuniculi infection. International Journal for Parasitology,2001,31(7):681-686.
31.Tsufit Gonen-Gross and Ofer Mandelboim. HLA-G Complexes Are Observed on the Cell Surface. Human Immunology.2007,68:227-232.
32. Christine Guillard, In'es Zidi, Celine Marcou, et al. Role of HLA-G in innate immunity through direct activation of NF-κB in natural killer cells. Molecular Immunology.2008,45:419-427.
33. Meike Mitsdoerffe, Bettina Schreiner, Bernd C. Kieseier, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-h in vitro and in vivo:rationale for the therapy of multiple sclerosis. Journal of Neuroimmunology 159 (2005) 155-164.
34. LeMaoult J, K Zafranloo, C Le Danff, et al. HLA-G up-regulates ILT2,ILT3ILT4, and KIR2DL4 in antigen presenting cells, NK cells and T cells. Faseb J,2005, 19:662.
35.Nakajima H, A Asai, A Okada, et al. Transcriptional regulation of ILT family receptors. J Immunol.2003,171:6611.
36. Pedersen AE, M Gad, MR Walter, et al. Induction of regulatory dendritic cells by dexamethasone and lalPha,25-Dihydroxy vitaminD(3). Immunol. Lett,2004: 91:63.
37. Papanikolaou NA, ER Vasileseu and N Suciu-Foca. Novel single nucleotide Polymorphisms in the human immune inhibitory immunoglobulin-like T cell receptor type4. Hum Immunol,200,65:700.
38. Hofmeister V, and EH Weiss. HLA-G modulates immune responses by diverse receptor interactions. Semin Cancer Biol.2003,13:317.
39. Shiroishi M, K Tsumoto, K Amano, et al. Human inhibitory receptors Ig-like transcript 2(ILT2) and ILT4 Compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Pro Natl Acad Sci USA.2003,100:8856.
40. Vasiliki Drossou-Agakidou, Florence Kanakoudi-Tsakalidou, Kosmas Sarafidis,,et al. In vivo effect of rhGM-CSF and rhG-CSF on monocyte HLA-DR expression of septic neonates. Cytokine,2002,18(5):260-265.
41. Kazunori Nakase, Kenkichi Kita, Hiroshi Anazawa, et al. Induction of interleukin-2 receptor alpha chain expression on immature acute myelocytic leukemia cells. Leukemia Research,1994,18(4):269-274
42. Sophie Lefebvre, Philippe Moreau, Virginie Guiard, et al. Molecular mechanisms controlling constitutive and IFN-y-inducible HLA-G expression in various cell. types. Journal of Reproductive Immunology,1999,43(2):213-224
43. Joel LeMaoult, Kamelia Zafaranloo, Caroline. Le Danff and Edgardo D. Carosella. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. The FASEB Journal.2005;19:662-664.
44.Abderrahim Naji, Antoine Durrbach, Edgardo D. Carosella, Nathalie Rouas-Freiss. Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways. Human Immunology,2007,68(4):233-239.
45. Philippe Rousseau, Magali Le Discorde, Gael Mouillot, et al. The 14 bp Deletion-Insertion polymorphism in the 3'UT region of the HLA-G gene influences HLA-G mRNA stability. Human Immunology,2003,64(11):1005-1010.
46. Vera Rebmann, Jens Regel, Dietmar Stolke, Hans Grosse-Wilde. Secretion of sHLA-G molecules in malignancies. Seminars in Cancer Biology,2003,13(5): 371-377.
47.Rabbani H, Schedvins K, et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism[J]. J Clin Invest.2002,110:1515-1523.
48. Iman Khalil-Daher, Beatrice Riteau, Catherine Menier,et al. Role of HLA-G versus HLA-E on NK function:HLA-G is able to inhibit NK cytolysis by itself. Journal of Reproductive Immunology,1999,43(2):175-182
49. Sheshgiri R, Rao V, Tumiati LC, Xiao R, Prodger JL, Badiwala M, et al. Progesterone induces human leukocyte antigen-g expression in vascular endothelial and smooth muscle cells. Circulation.2008,118(14 Suppl):58-64.
50. Yie SM, Li LH, Li GM, Xiao R, Librach CL. Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum Reprod.2006,21(1):46-51.
51. Moreau P, Faure O, Lefebvre S, Ibrahim EC, O BM, Gourand L, et al. Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. Transplant Proc.2001,33(3):2277-80.
52. Nasef A, Chapel A, Mazurier C, Bouchet S, Lopez M, Mathieu N, et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr.2007,13(4-5):217-26.
53. Mitsdoerffer M, Schreiner B, Kieseier BC, Neuhaus O, Dichgans J, Hartung HP, et al. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo:rationale for the therapy of multiple sclerosis. J Neuroimmunol.2005,159(1-2):155-64.
54. Ugurel S, Rebmann V, Tilgen W, Grosse-Wilde H, Reinhold U. High serum levels of sHLA-G in melanoma patients induced by interferon-alpha therapy. J Invest Dermatol.2000,114(4):835.
55. Bamberger AM, Jenatschke S, Schulte HM, Loning T, Bamberger MC. Leukemia inhibitory factor (LIF) stimulates the human HLA-G promoter in JEG3 choriocarcinoma cells. J Clin Endocrinol Metab.2000,85(10):3932-36.
56. Gazit E, Sherf M, Balbin E, Muratov A, Goldstein I, Loewenthal R. HLA-G expression is induced in Epstein-Barr virus-transformed B-cell lines by culture conditions. Hum Immunol.2007,68(6):463-68.
57. Rivero A, Lozano JM, Gonzalez R, Garcia-Jurado G, Camacho A, Torres-Cisneros J, et al. Nucleoside reverse transcriptase inhibitors are able and protease inhibitors unable to induce the tolerogenic molecule HLA-G 1 on monocytes from HIV-1 infected patients. Hum Immunol.2007,68(4):303-6.
58. Megret F, Prehaud C, Lafage M, Moreau P, Rouas-Freiss N, Carosella ED, et al. Modulation of HLA-G and HLA-E expression in human neuronal cells after rabies virus or herpes virus simplex type 1 infections. Hum Immunol.2007,68(4): 294-302.
59. Lafon M, Prehaud C, Megret F, Lafage M, Mouillot G, Roa M, et al. Modulation of HLA-G expression in human neural cells after neurotropic viral infections. J Virol.2005,79(24):15226-37.
60. Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H. Detection of HLA-G5 secreting cells. Hum Immunol.2003,64(11):1017-24.
61. Blanco O, Tirado I, Munoz-Fernandez R, Abadia-Molina AC, Garcia-Pacheco JM, Pena J, et al. Human decidual stromal cells express HLA-G:Effects of cytokines and decidualization. Hum Reprod.2008,23(1):144-52.
62. Pizzato N, Garmy-Susini B, Le BP, Lenfant F. Down-regulation of HLA-G 1 cell surface expression in human cytomegalovirus infected cells. Am J Reprod Immunol.2003,50(4):328-33.
63. Yang Y, Geraghty DE, Hunt JS. Cytokine regulation of HLA-G expression in human trophoblast cell lines. J Reprod Immunol.1995,29(3):179-95.
64. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse:A molecular machine controlling T cell activation[J]. Science,1999,285(5425): 207-208.
65. Pacheco R, Martinez-Navio JM, Leune M, et al. CD26, adenosine deam inase, and adenosine receptors mediate costimulatory signals in the immunological synapse[J]. Proc Natl Acad Sci USA,2005,102(27):9583-9588.
66. Faroudi M, Utzny C, Salio M, et al. Lytic versus stimulatory synapsein cytotoxic T lymphocyte/target cell interaction:M an infestation of a dual activation threshold[J]. Proc Natl Acad Sci USA,2003,100(24):14145-14150.
67.Wulfing C, Davis MM. A recepter/cytoskeletal movement triggered by costimulating during T cell ctivating[J]. Science,1998,282(5397):2266-2269.
68. Davis DM, Chin I, Fassett M, et al. The human natural killer cell immune synapse [J]. Proc Natl Acad Sci USA,1999,96(26):15062-15067.
69.Vyas YM, Maniar H, Lyddane CE, et al. Ligand binding to inhibitory killer cell Ig-like recepters induce colocalization with Src homology domain 2-containing protein tyrosine I and interruption of ongoing activation signals[J]. J Immunol, 2004,173(3):1571-1578.
70. Tabiasco J, Vereelone A, Meggetto F, et al. Acquisition of viral receptor by NK cells through immunological synapse [J]. J Immunol,2003,170(12):5993-5998.
71.Poupot M, Fourine JJ. Spontaneous membrane transfer through homotypic synapse between lyphoma cells [J]. J Immunol.2003,171(5):2517-2523.
72.LeMaoult J, Caumartin J, Daouya M, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood, 2007,109(5):2040-8
73.Caumartin J, Favier B, Daouya M, et al. Trogocytosis-based generation of suppressive NK cells. Embo J,2007,26(5):1423-33.
1. Le Morvan C, Cogne M, Troutaud D, Charmes JP, Sauvage P, Drouet M. Modification of HLA expression on peripheral lymphocytes and monocytes during aging. Mech Ageing Dev.1998,105(3):209-20.
2. Suzuki H, Higuchi M, Hasegawa T, et al. Tissue array analysis of the aberrant expression of HLA class I molecules in human non small cell lung cancer. Gan To Kagaku Ryoho.2006,33(12):1713-6.
3. Kitamura H, Honma I, Torigoe T, et al. Down-regulation of HLA class I antigen is an independent prognostic factor for clear cell renal cell carcinoma. J Urol. 2007,177(4):1269-72.
4. Li J, Yang Y, Inoue H, et al. The expression of costimulatory molecules CD80 and CD86 in human carcinoma cell lines:its regulation by interferon gamma and interleukin-10. Cancer Immunol Immunother,1996,43(4):213-219.
5. Chai JG, Vendetti S, Amofah E, Dyson J, Lechler R. CD152 ligation by CD80 on T cells is required for the induction of unresponsiveness by costimulation-deficient antigen presentation. J Immunol.2000,165(6):3037-42.
6. Vlad QPiazza F,Colovai A. Interleukin-10 induces the upregulation of the inhibitory receptor ILT4 in monocytes from HIV positive individuals. Hum Immunol.2003; 64(5):483-489.
7.Lucy Cassar, He Li, Fang-Xu Jiang, Jun-Ping Liu. TGF-P induces telomerase-dependent pancreatic tumor cell cycle arrest. Molecular and Cellular Endocrinology, In Press, Corrected Proof, Available online 6 February 2010.
8. Li Zeng, Colleen O'Connor, Jiayou Zhang. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine,2010,49(3):294-302.
9. Lorenzo Moretta, Roberto Biassoni, Cristina Bottino, et al. Human NK cells and their receptors. Microbes and Infection,2002,4(15):1539-1544.
10. Hsing-Chun Kuo, Wu-Hsien Kuo, Yean-Jang Lee. Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo. Cancer Letters,2006,234(2):199-208.
11. Nishimura H,Okazaki T,Tanaka Y.Autoimmune medilated cardiomyopathy in PD-1 receptor-deficient mice.Science,2001;291:319-323
12. Mitsuaki I,Hisanori K,Jun-ichi S. T cell costimulation in the development of cardiac allograft vasculopathy Arteriosclerosis,Thrombosis,and Vascular. Biology.2006;26:1447-1456
13. James L.Riley,Carl H.J. The CD28 family:a T-cell rheostat for therapeutic control of T-cell activation. Blood,2005;105:13-21
14. Oht su A, Yoshida S, Saijo N,et al. Disparities in gast ric cancer chemotherapy between the East and West [J]. J Clin Oncol,2006,24 (14):2188.
15. Cortesini R,LeMaoult J,Ciubotariu R,et al. CD8+CD28-T suppressor cells and theinduction of antigen-specific,antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev,2001,182:201-206.
16. Chang CC,Ciubotariu R,Manavalan JS,et al.Tolerization of dendritic cells by T(S)cells:the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol, 2002,3(3):237-243.
17. Steinman RM,Hawiger D,Nussenzweig MC.Tolerogenic dendritic cells.Annu RevImmunol,2003,21:685-711.
18. Coates PT,Colvin BL,Kaneko K,et al. Pharmacologic,biologic,and genetic engineering approaches to potentiation of donor-derived dendritic cell tolerogenicity. Transplantation,2003,75:32-36.
19. Expression and function of immunoglobin-like transcripts on tolerogenic dendritic cells. Human immunology,2009,70:353-356.
20.Lutz MB,Schuler G. Immature,semi-mature and fully mature dendritic cells:which signals induce tolerance or immunity.Trends Immunol,2002,23:445-449.
21.Xiao BQWu XC,Yang JS,et al.Therapeutic potential of IFN-gmodified dendritic cells in acute and chronic experimental allergic encephalomyelitis. Int Immunol, 2004,16:13-22.
22. Adorini L,Giarratana N,Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells.Semi Immunol,2004,16:127-134.
23. Li G,Kim YJ,Broxmeyer HE. Macrophage colony-stimulating factor drives cord blood monocyte differentiation into IL-10(high)-IL-12absent dendritic cells with tolerogenic potential.J Immunol,2005,174:4706-4717.
24.Taams LS, Akbar AN. Peripheral generation and function of CD4+CD25+ regulatory T cells.Curr Top Microbiol Immunol,2005,293:115-131.
25.Bohana-Kashtan O, Civin CI. Fas ligand as a tool for immunosuppression and generation of immune tolerance.Stem Cells,2004,22:908-924.
26.Mellor AL,Munn DH. IDO expression by dendritic cells:tolerance and tryptophan catabolism. Nat Rev Immunol,2004,4:762-774.
27. Siyuan Liang, Vladimir Ristich, Hisashi Arase,et al. Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. PNAS,2008,17:8357-8362.
28. Suciu-Foca N, Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol.2007,248:59-67.
29. Rutella S,Bonanno G,Pierelli L,et al. Granulocyte colonystimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha.Eur J Immunol,2004,34:1291-1302.
30. Vlad G, Liu Z, Zhang QY, Cortesini R, Suciu-Foca N. Immunosuppressive activity of recombinant ILT3. Int Immunopharmacol.2006,6:1889-94.
31.Corinti S,Albanesi C,la Sala A,et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol,2001,166:4312-4318.
32.Vlad G, Cortesini R, Suciu-Foca N. CD8+T suppressor cells and the ILT3 master switch. Hum Immunol.2008;69:681-6.
33.Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad SciUSA.2003;100:8856-61.
34. Cai Zhang, Jian Zhang, Haiming Wei, Zhigang Tian. Imbalance of NKG2D and its inhibitory counterparts:How does tumor escape from innate immunity? International Immunopharmacology,2005,5(7-8):1099-1111.
35. Yuping Sun, Jie Liu, Ping Gao, et al. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest,2008, 134:783-788
36. Y. Fukushima, Y. Oshika, M. Nakamura, T. Tokunaga, H. Hatanaka and Y. Abe et al, Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mol Med,1998,2(3):349-351.
37. K. Leelawat, S Engprasert, U. Pongchai-rerk, et al. No expression of human leukocyte antigen G (HLA-G) in colorectal cancer cells, J Med Assoc Thai,2004, 87 (7):816-818.
38. Alessandro Poggi, Maria Raffaella Zocchi. Role of bone marrow stromal cells in the generation of human CD8+regulatory T cells. Human Immunology,2008, 69(11):755-759.
39. R.H. McIntire, J.S. Hunt. Antigen presenting cells and HLA-G-a review. Placenta,2005,26(Supplement 1):S104-S109.
40.Jonathan M. Wilson, P. Louise Coletta, Richard J. Cuthbert. Macrophage Migration Inhibitory Factor Promotes Intestinal Tumorigenesis. Gastroenterology, 2005,129(5):1485-1503.
1. S. Kovats, E.K. Main, C. Librach, M. Stubblebine, S.J. Fisher and R. DeMars, A class I antigen, HLA-G, expressed in human trophoblasts, Science.1990,248 (4952):.220-223.
2. S.A. Ellis, M.S. Palmer and A.J. McMichael, Human trophoblast and the choriocarcinoma cell line BeWo express a truncated HLA Class I molecule, J Immunol.1990,144 (2):731-735.
3. Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A, Wiendl H. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation.Blood.2007,110(2):568-77.
4. N. Rouas-Freiss, R.M. Goncalves, C. Menier, J. Dausset and E.D.D. Carosella, Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci.1997,94 (21):11520-11525
5. E. D. Carosella, B. Favier, N. Rouas-Freiss, P. Moreau, and J. LeMaoult.Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood, 2008; 111(10):4862-4870.
6. Abderrahim Naji, Antoine Durrbach, Edgardo D. Carosella, Nathalie Rouas-Freiss. Soluble HLA-G and HLA-G1 Expressing Antigen-Presenting Cells Inhibit T-Cell Alloproliferation through ILT-2/ILT-4/FasL-Mediated Pathways. Human Immunology,2007,68:233-239
7. Christian A. Gleissner, Thomas J. Dengler. Induction of ILT expression on nonprofessional antigen presenting cells:Clinical applications. Human Immunology,2009,70:357-359
8. Y. Sun, J. Liu, P. Gao, Y. Wang, and C. Liu. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest, October 1,2008; 134(4):783-788.
9. Zhang Yi, Liu Yang, Lu Nan, et al. Rapid detection of HLA genes expression in Peripheral Blood Mononuclear Cell of Gastric Cancer Patients by reverse transcriptase polymerase chain reaction.978-1-4244-2902-8/09(?)2009 IEEE
10.Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H. Quantitative real-time RT-PCR data analysis:current concepts and the novel "gene expression's CT difference" formula. J Mol Med.2006,84(11):901-10.
11. Donald CE, Qureshi F, Burns MJ, Holden MJ, Jr Blasic JR, Woolford AJ. An inter-platform repeatability study investigating real-time amplification of plasmid DNA. BMC Biotechnol.2005,5:15.
12. Geraghty DE, Koller BH, Orr HT. A human major histocompatibility complex class Ⅰ gene that encodes a protein with a shortened cytoplasmic segment. Proc Natl Acad Sci USA.1987,84(24):9145-49.
13. Tomasoni S, Remuzzi G, Benigni A. Allograft rejection:acute and chronic studies. Contrib Nephrol.2008,159:122-34.
14. Fujii T, Ishitani A, Geraghty DE. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J Immunol.1994, 153(12):5516-24.
15. P. Le Bouteiller. HLA-G et immunite placentaire localeHLA-G and local placental immunity. Gynecologie Obstetrique & Fertilite,2003,31:782-785
16. Astrid M. Kolte, Rudi Steffensen, Henriette S, et al. Nielsen. Study of the structure and impact of human leukocyte antigen (HLA)-G-A, HLA-G-B, and HLA-G-DRB1 haplotypes in families with recurrent miscarriage. Human Immunology, In Press, Corrected Proof, Available online 19 February 2010
17. Lemaoult J, Le DM, Rouas-Freiss N, Moreau P, Menier C, Mccluskey J, et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens.2003,62(4):273-84.
18. Carosella ED, Moreau P, Lemaoult J, Rouas-Freiss N. HLA-G:from biology to clinical benefits. Trends Immunol.2008,29(3):125-32.
19. M. Urosevic, J. Willers, B. Mueller, W. Kempf, G. Burg and R. Dummer, HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas, Blood.2002,99 (2):609-617
20. P. Paul, F.A. Cabestre, F.A. Le Gal, Ⅰ. Khalil-Daher, C. Le Danff and M. Schmid et al., Heterogeneity of HLA-G gene transcription and protein expression in malignant melanoma biopsies, Cancer Res.1999,59 (8):1954-1960.
21. S. Aractingi, J. Kanitakis, S. Euvrard, C. Le Danff and E.D Carosella, Selective expression of HLA-G in malignant and premalignant skin specimens in kidney transplant recipients, Int J Cancer.2003,106 (2):232-235。
22. D.E. Hansel, A. Rahman, R.E. Wilentz, M. Shih Ie, M.T. McMaster and C.J. Yeo et al., HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract, Int J Gastrointest Cancer.2005,35 (1):15-23.
23. Y. Fukushima, Y. Oshika, M. Nakamura, T. Tokunaga, H. Hatanaka and Y. Abe et al., Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells, Int J Mol Med.1998,2 (3):349-351.
24. S.R. Ye, H. Yang, K. Li, D.D. Dong, X.M. Lin and S.M. Yie, Human leukocyte antigen G expression:as a significant prognostic indicator for patients with colorectal cancer, Mod Pathol.2007,20 (3):375-383.
25. M. Urosevic, M.O. Kurrer, J. Kamarashev, B. Mueller, W. Weder and G. Burg et al., Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class Ⅰ loss and interleukin-10 production, Am J Pathol.2001,159 (3):817-824.
26.B. Davidson, B. Risberg, A. Berner, C.W. Bedrossian and R. Reich, The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma, Semin Diagn Pathol.2006,23 (1):35-43.
27.B. Davidson, B. Risberg, A. Berner, C.W. Bedrossian and R. Reich, The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma, Semin Diagn Pathol.2006,23 (1):35-43.
28. E.C. Ibrahim, N. Guerra, M.J. Lacombe, E. Angevin, S. Chouaib and E.D Carosella et al., Tumor-specific up-regulation of the nonclassical class Ⅰ HLA-G antigen expression in renal carcinoma, Cancer Res.2001,61 (18):6838-6845.
29. J. Bukur, V. Rebmann, H. Grosse-Wilde, H. Luboldt, H. Ruebben and I. Drexler et al., Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma, Cancer Res.2003,63 (14):4107-4111.
30. J. Bukur, B. Malenica, C. Huber and B. Seliger, Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response, Hum Immunol.2003,64 (11): 1081-1092.
31. C. Ibrahim el, Y. Allory, F. Commo, et al. Altered pattern of major histocompatibility complex expression in renal carcinoma. Am J Pathol.2003,162 (2):501-508.
32. B.F. Barrier, B.S. Kendall, K.L. Sharpe-Timms and E.R. Kost, Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma, Gynecol Oncol.2006,103 (1):25-30.
33. M. Ponte, C. Cantoni, R. Biassoni, et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy:decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G 1-specific receptor. Proc Natl Acad Sci USA.1999,96 (10):5674-5679.
34. D.R. Bainbridge, S.A. Ellis and I.L. Sargent, HLA-G suppresses proliferation of CD4(+) T-lymphocytes, J Reprod Immunol.2000,48 (1):17-26.
35. S. Fournel, M. Aguerre-Girr, X. Huc, et al., Cutting edge:soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J Immunol.2000,164 (12):6100-6104.
36. S. Rajagopalan and E.O. Long, A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med.1999, 189(7):1093-1100.
37. Contini P, Ghio M, Poggi A, et al. Soluble HLA-A,-B,-C and-G molecules induce apoptosis in T and NK CD8+cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol.2003,33(1):125-34.
38. Puppo F, Contini P, Ghio M, Indiveri F. Soluble HLA class I molecules/CD8 ligation trigger apoptosis of CD8+cells by Fas/Fas-ligand interaction. Scientific World Journal.2002,2:421-23.
39. Fang CY, Wu XW, Liang ZH, et al. Immune tolerance inducing effects of soluble human leucocyte antigen Gl on natural killer cells and T cells. Zhonghua Yi Xue Za Zhi.2003,83(7):584-87.
40. Bahri R, Hirsch F, Josse A, Rouas-Freiss N, Bidere N, Vasquez A, et al. Soluble HLA-G inhibits cell cycle progression in human alloreactive T lymphocytes. J Immunol.2006,176(3):1331-39.
41. Lemaoult J, Zafaranloo K, Le DC, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. Faseb J. 2005,19(6):662-64.
42. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol.2000,48(1):17-26.
43. N. Lila, N. Rouas-Freiss, J. Dausset, A. Carpentier and E.D Carosella, Soluble HLA-G protein secreted by allo-specific CD4+T cells suppresses the allo-proliferative response:a CD4+T cell regulatory mechanism, Proc Natl Acad Sci USA.2001,98 (21):12150-12155.
44. Maejima M, Fujii T, Kozuma S, Okai T, Shibata Y, Taketani Y. Presence of HLA-G-expressing cells modulates the ability of peripheral blood mononuclear cells to release cytokines. Am J Reprod Immunol.1997,38(2):79-82.
45. Hamai Y, Fujii T, Yamashita T, et al. Peripheral blood mononuclear cells from women with recurrent abortion exhibit an aberrant reaction to release cytokines upon the direct contact of human leukocyte antigen-G-expressing cells. Am J Reprod Immunol.1998,40(6):408-13.
46. Hamai Y, Fujii T, Yamashita T, Miki A, et al. The expression of human leukocyte antigen-G on trophoblasts abolishes the growth-suppressing effect of interleukin-2 towards them. Am J Reprod Immunol.1999,41(2):153-58.
47. Kanai T, Fujii T, Unno N, et al. Human leukocyte antigen-G-expressing cells differently modulate the release of cytokines from mononuclear cells present in the decidua versus peripheral blood.2001,45(2):94-99.
48. Rieger L, Hofmeister V, Probe C, Dietl J, et al. Thl-and Th2-like cytokine production by first trimester decidual large granular lymphocytes is influenced by HLA-G and HLA-E. Mol Hum Reprod.2002,8(3):255-61.
49. Van Der Meer A, Lukassen HG, Van Cranenbroek B, Weiss EH, Braat DD, Van Lierop MJ, et al. Soluble HLA-G promotes Thl-type cytokine production by cytokine-activated uterine and peripheral natural killer cells. Mol Hum Reprod. 2007,13(2):123-33.
50. Joly E, Hudrisier D. What is trogocytosis and what is its purpose?. Nat Immunol. 2003,4(9):815.
51. Lemaoult J, Caumartin J, Daouya M, Favier B, Le RS, Gonzalez A, et al. Immune regulation by pretenders:cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood.2007,109(5):2040-48.
52. Feger U, Tolosa E, Huang YH, Waschbisch A, Biedermann T, Melms A, et al. HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood.2007,110(2):568-77.
53. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, Carosella ED, et al. Trogocytosis-based generation of suppressive NK cells. Embo J.2007,26(5): 1423-33.
54. Selmani Z, Naji A, Zidi I, Favier B, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+regulatory T cells. Stem Cells.2008,26(1):212-22.
55. Le MA, Noel G, Birebent B, Grosset JM, Vu N, De Guibert S, et al. Soluble human leucocyte antigen-G molecules in peripheral blood haematopoietic stem cell transplantation:a specific role to prevent acute graft-versus-host disease and a link with regulatory T cells. Clin Exp Immunol.2008,152(1):50-56.
56.张义,邹雄,杨晓静,李晓丽,赵胜梅,高艳景.淋巴细胞HLA-B表达与胃癌分化转移的关系.中华肿瘤杂志,2007,29：49-52
57. Lu N, Wan F, Yang X, Wang C, Yi Z, et al. Qa-2 mRNA in peripheral blood mononuclear cells, a Potential Marker for Acute Allograft Rejection. Med Sci Monit,2009,15(4):BR99-105.
58. P. Paul, N. Rouas-Freiss, I. Khalil-Daher, P. Moreau, B. Riteau and F.A. Le Gal et al., HLA-G expression in melanoma:a way for tumor cells to escape from immunosurveillance, Proc Natl Acad Sci USA.1998,95 (8):4510-4515.
59. H.M. Hurks, M.M. Valter, L. Wilson, I. Hilgert, P.J. van den Elsen and M.J. Jager, Uveal melanoma:no expression of HLA-G, Invest Ophthalmol Vis Sci.2001,42 (13):3081-3084.
60.Fukushima Y, Oshika Y, Nakamura M, et al. Increase expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int J Mol Med, 1998,2(3):349-51.
61. B.F. Barrier, B.S. Kendall, K.L. Sharpe-Timms and E.R. Kost, Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma, Gynecol Oncol.2006,103 (1):25-30.
62. Erinn Downs-Kelly, Andrew E. Schade and Donna E. Hansel. The role of HLA-G in gastrointestinal inflammatory disease and malignancy. Seminars in Cancer Biology.2007,17 (6):451-458
63. Myriam Onno, Gaelle Le Friec, Celine Pangault, et al. Modulation of HLA-G antigens expression in myelomonocytic cells. Human Immunology,2000,61(11):1086-1094.
64. Y. Fukushima, Y. Oshika, M. Nakamura, T. Tokunaga, et al., Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells, Int J Mol Med.1998,2 (3):349-351.
65. K. Leelawat, S. Engprasert, U. Pongchai-rerk, S. Tuchinda, C. Suthipintawong and V. Leardkamolkarn, No expression of human leukocyte antigen G (HLA-G) in colorectal cancer cells, J Med Assoc Thai.2004,87 (7):816-818.
66. D.E. Hansel, A. Rahman, R.E. Wilentz, et al., HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract, Int J Gastrointest Cancer.2005,35(1):15-23.
67. J. Caumartin, B. Favier, M. Daouya, C. Guillard, P. Moreau and E.D Carosella et al., Trogocytosis-based generation of suppressive NK cells, Embo J.2007,26 (5):1423-1433.
1. Hiromichi Kawaida, Koji Kono, Akihiro Takahashi. et al. Distribution of CD4(+) CD25high regulatory T-cells in tumor-draining lymph nodes in patients with gastric cancer. Journal of Surgical Research,2005,124,:151-157
2. Stefanie Gross, Peter Walden. Immunosuppressive mechanisms in human tumors:Why we still cannot cure cancer. Immunology Letters,2008,116:7-14.
3. Katsuiku Hirokawa, Masanori Utsuyama, Toshiaki Ishikawa. et al. Decline of T cell-related immune functions in cancer patients and an attempt to restore them through infusion of activated autologous T cells. Mechanisms of Ageing and Development.2009,130:86-91
4. John K. Petty, Ken He, Christopher L.et al. Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). The American Journal of Surgery,2002,183:512-518
5. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science.2000,6:290 (5489):84-9.
6. George Vlad, Raffaello Cortesini, Nicole Suciu-Foca. CD8+ T suppressor cells and the ILT3 master switch. Human Immunology,2008,69:681-686.
7. Jinyi Zhang, Ally-Khan Somani, Katherine A. Siminovitch. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Seminars in Immunology,2000,12(4):361-378.
8. Yuping Sun, Jie Liu, Ping Gao, et al. Expression of Ig-Like Transcript 4 Inhibitory Receptor in Human Non-small Cell Lung Cancer. Chest, 2008,134:783-788.
9.Boris Fedoric, Ravi Krishnan. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunology Letters, 2008,120:49-56.
10. Favier B, Lemaoult J, Lesport E. et al. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J.2010;24(3):689-99.
11. Christian A. Gleissner, Thomas J. Dengler. Induction of ILT expression on nonprofessional antigen presenting cells:Clinical applications. Human Immunology,2009 70(5):357-359.
12. Homfeister,V and EH Weiss. HLA-G modulates immune responses by diverse receptor interactions.Semin Cancer Biol,2003,13:317.
13.A. Monsiva'is-Urenda, P. Ni-no-Moreno, C. Abud-Mendoza, et al. Analysis of expression and function of the inhibitory receptor ILT2 in peripheral blood mononuclear cells frompatients with systemic lupus erythematosus (SLE). Journal of Autoimmunity,2007,29:97-105.
14.Xin-Sheng Ju, Christine Hacker, Barbara Scherer, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene,2004,31:159-164.
15.Shiroishi M, K Tsumoto, K Amno, et al. Human inhibitory receptors Ig-like transcriptor 2(ILT2) and ILT4 compete with CD8 for MHC-class I binding and bind preferentially to HLA-G. Natl Acad Sci USA,2003,100:8856.
16. John S. Manavalan, Paola C. Rossi, George Vlad, et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transplant Immunology,2003,11 (3-4):245-258.
17.Juan Wu and Anatolij Horuzsko. Expression and function of immunoglobin-like transcripts on tolerogenic dendritic cells. Human Immunology.2009,70: 353-356.
18. Urban Svajger, Alenka Vidmar, Matjaz Jeras. Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ILT3 and ILT4. International Immunopharmacology,2008,8(7):997-1005
19. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, et al. Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by humandendritic cells and down-regulated following activation. Gene, 2004:331:159-64.
20. Suciu-Foca N, Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol.,2007:248:59-67.
21. Idan Tamir, Joseph M Dal Porto, John C Cambier. Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2:regulators of B cell signal transduction. Current Opinion in Immunology,2000,12(3):307-315.
22. Leonie S. Taams, Jocea M.R. van Amelsfort, Machteld M. Tiemessen. et al. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Human Immunology,2005,66:222-230.
23. Vlad G, Cortesini R, Suciu-Foca N. CD8+T suppressor cells and the ILT3master switch. Hum Immunol,2008:69:681-6.
24. Ariel Munitz. Inhibitory receptors on myeloid cells:New targets for therapy? Pharmacology & Therapeutics, January 2010,125(1):128-137.
25. Judith Leitner, Katharina Grabmeier-Pfistershammer, Peter Steinberger. Receptors and ligands implicated in human T cell costimulatory processes. Immunology Letters,2010,128(2):89-97.
1 Waldhauer Ⅰ, Steinle A:NK cells and cancer immunosurveillance. Oncogene 2008; 6:5932-5943.
2 Seliger B:Molecular mechanisms of MHC class Ⅰ abnormalities and APM components in human tumors. Cancer Immunol Immunother 2008; 57: 1719-1726.
3 Holling TM, Schooten E, van Den Elsen PJ:Function and regulation of MHC class Ⅱ molecules in T-lymphocytes:of mice and men. Hum Immunol 2004; 65:282-290.
4 Groothuis T, Neefjes J:The ins and outs of intracellular peptides and antigen presentation by MHC class Ⅰ molecules. Curr Top Microbiol Immunol 2005; 300:127-148.
5 Williams A, Peh CA, Elliott T:The cell biology of MHC class I antigen presentation. Tissue Antigens 2002; 59:3-17.
6 Chiba M, Ishii N, Ishioka T, et al:Topographic study of Helicobacter pylori and HLA-DR antigen expression on gastric epithelium. J Gastroenterol 1995; 30:149-155.
7 Maeurer MJ, Gollin SM, Martin D, et al:Tumor escape from immune recognition:lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996; 98:1633-1641.
8 Plaksin D, Gelber C, Feldman M, et al:Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. Proc Natl Acad Sci USA 1988; 85:4463-4467.
9 Schefe JH, Lehmann KE, Buschmann IR, et al:Quantitative real-time RT-PCR data analysis:current concepts and the novel "gene expression's CT difference" formula. J Mol Med 2006; 84:901-910.
10 Breton F. Barrier, Brian S, et al:Characterization of human leukocyte antigen-G(HLA-G) expression in endometrial adenocarcinoma. ynecologic Oncology 2006; 103:25-30.
11 Nathalie Rouas-Freiss, Philippe Moreau, Catherine Menier, et al:HLA-G in cancer:a way to turn off the immune system. Seminars in Cancer Biology 2003; 13:325-336.
12 Collins RW:Human MHC class I chain related (MIC) genes:their biological function and relevance to disease and transplantation. Eur J Immunogenet 2004; 31:105-114.
13 Wedekind C, Walker M, Little TJ:The separate and combined effects of MHC genotype, parasite clone, and host gender on the course of malaria in mice. BMC Genet 2006; 7:55.
14 Wu JD, Atteridge CL, Wang X, et al: Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation. Clin Cancer Res 2009; 15:632-640.
15 Le Morvan C, Cogne M, Drouet M:HLA-A and HLA-B transcription decrease with ageing in peripheral blood lymphocytes. Clin Exp Immunol 2001:125:245-250.
16 Abendroth A, Arvin A:Varicella-zoster virus immune evasion. Immunol Rev 1999; 168:143-156.
17 Morrow G, Slobedman B, Cunningham AL, et al: Varicella-zoster virus productively infects mature dendritic cells and alters their immune function. J Virol 2003; 77:4950-4959.
18 Lanier.L.L. NK cell receptors. Annu.Rev.Immuol 1998; 16:359-393.
19 Moretta.L., Biassoni.R., Bottino.C., et al: NK-cell receptors. Immunol.Today 2000; 21:420-422.
20 Trowsdale.J. Genetic and functional relationships between MHC and NK receptor genes. Immunity 2001; 15:363-374.
21 Yokoyama.W.M. & Plougastel, B.F. Immune functions encoded by the natural killer gene complex. Nature Rev. Immunol.2003; 3:304-316.
22 Kim S, Poursine-Laurent J, Truscott SM, et al: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005:436:709-713.
23 Zhang Y, Zou X, Yang XJ, et al: Relationship between the expression of human leukocyte antigen-B in peripheral blood leukocytes and the differentiation and metastasis of gastric carcinoma. Zhonghua Zhong Liu Za Zhi 2007; 29:49-52 [in Chinese].
24 Mouillot G, Marcou C, Zidi I, et al: Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 2007; 68:277-285.
25 Zeng MH, Fang CY, Wang SS, et al A study of HLA-G1 protecting porcine endothelial cells against human natural killer cell-mediated cytotoxicity. Transplant Proc 2006; 38:3312-3314.